Ziprasidone - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (25)Enzymes (5)

Targets (25)Enzymes (5)Biointeractions (31)

Identification

Name

Ziprasidone

Accession Number

DB00246 (APRD00540)

Type

Small Molecule

Groups

Approved

Description

Ziprasidone (marketed as Geodon, Zeldox) was the fifth atypical antipsychotic to gain FDA approval (February 2001). Ziprasidone is Food and Drug Administration (FDA) approved for the treatment of schizophrenia, and the intramuscular injection form of ziprasidone is approved for acute agitation in schizophrenic patients. Ziprasidone has also received approval for acute treatment of mania associated with bipolar disorder. [Wikipedia]

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

Ziprasidona

Ziprasidone

Ziprasidonum

External IDs

Not Available

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Ziprasidone hydrochloride	216X081ORU	122883-93-6	NZDBKBRIBJLNNT-UHFFFAOYSA-N	Details
Ziprasidone mesylate trihydrate	3X6SAX83JZ	199191-69-0	WLQZEFFFIUHSJB-UHFFFAOYSA-N	Details

Product Images

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Gd-ziprasidone	Capsule	80 mg	Oral	Genmed A Division Of Pfizer Canada Inc	Not applicable	Not applicable	Canada
Gd-ziprasidone	Capsule	40 mg	Oral	Genmed A Division Of Pfizer Canada Inc	Not applicable	Not applicable	Canada
Gd-ziprasidone	Capsule	60 mg	Oral	Genmed A Division Of Pfizer Canada Inc	Not applicable	Not applicable	Canada
Gd-ziprasidone	Capsule	20 mg	Oral	Genmed A Division Of Pfizer Canada Inc	Not applicable	Not applicable	Canada
Geodon	Injection, powder, lyophilized, for solution	20 mg/mL	Intramuscular	TYA Pharmaceuticals	2003-12-23	Not applicable	US
Geodon	Capsule	80 mg/1	Oral	Roerig	2013-11-01	Not applicable	US
Geodon	Capsule	20 mg/1	Oral	Unit Dose Services	2001-02-05	Not applicable	US
Geodon	Capsule	20 mg/1	Oral	Stat Rx USA	2001-02-05	Not applicable	US
Geodon	Capsule	60 mg/1	Oral	Remedy Repack	2010-12-20	2017-06-21	US
Geodon	Injection, powder, lyophilized, for solution	20 mg/mL	Intramuscular	Cardinal Health	2003-12-23	Not applicable	US
Geodon	Capsule	60 mg/1	Oral	Rebel Distributors	2001-02-05	Not applicable	US
Geodon	Capsule	40 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Geodon	Capsule	60 mg/1	Oral	Roerig	2013-11-01	Not applicable	US
Geodon	Capsule	60 mg/1	Oral	Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc	2012-03-27	Not applicable	US
Geodon	Injection, powder, lyophilized, for solution	20 mg/mL	Intramuscular	Remedy Repack	2015-02-13	2017-03-14	US
Geodon	Capsule	40 mg/1	Oral	Roerig	2001-02-05	Not applicable	US
Geodon	Capsule	80 mg/1	Oral	Remedy Repack	2010-12-20	2017-03-16	US
Geodon	Capsule	20 mg/1	Oral	Cardinal Health	2001-02-05	Not applicable	US
Geodon	Capsule	80 mg/1	Oral	Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc	2001-02-05	Not applicable	US
Geodon	Capsule	40 mg/1	Oral	Cardinal Health	2001-02-05	Not applicable	US
Geodon	Injection, powder, lyophilized, for solution	20 mg/mL	Intramuscular	Roerig	2003-12-23	Not applicable	US
Geodon	Capsule	20 mg/1	Oral	Rebel Distributors	2001-02-05	Not applicable	US
Geodon	Capsule	20 mg/1	Oral	Roerig	2013-11-01	Not applicable	US
Geodon	Capsule	80 mg/1	Oral	Rebel Distributors	2001-02-05	Not applicable	US
Geodon	Capsule	60 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Geodon	Capsule	60 mg/1	Oral	Roerig	2001-02-05	Not applicable	US
Geodon	Capsule	20 mg/1	Oral	Remedy Repack	2010-12-20	Not applicable	US
Geodon	Capsule	80 mg/1	Oral	Cardinal Health	2001-02-05	Not applicable	US
Geodon	Capsule	20 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2010-11-05	Not applicable	US
Geodon	Capsule	60 mg/1	Oral	Cardinal Health	2001-02-05	Not applicable	US
Geodon	Capsule	20 mg/1	Oral	Roerig	2001-02-05	Not applicable	US
Geodon	Injection, powder, lyophilized, for solution	20 mg/mL	Intramuscular	Roerig	2017-07-24	Not applicable	US
Geodon	Capsule	40 mg/1	Oral	Rebel Distributors	2001-02-05	Not applicable	US
Geodon	Capsule	20 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Geodon	Capsule	40 mg/1	Oral	Roerig	2013-11-01	Not applicable	US
Geodon	Capsule	80 mg/1	Oral	Roerig	2001-02-05	Not applicable	US
Geodon	Capsule	40 mg/1	Oral	Remedy Repack	2010-12-20	2017-06-21	US
Geodon	Capsule	80 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Zeldox	Capsule	60 mg	Oral	Pfizer	2008-01-04	Not applicable	Canada
Zeldox	Capsule	20.0 mg	Oral	Pfizer	2008-01-04	Not applicable	Canada
Zeldox	Capsule	80 mg	Oral	Pfizer	2008-01-04	Not applicable	Canada
Zeldox	Capsule	40 mg	Oral	Pfizer	2008-01-04	Not applicable	Canada
Ziprasidone	Capsule	60 mg/1	Oral	Remedy Repack	2013-03-27	2017-01-28	US
Ziprasidone	Capsule	60 mg/1	Oral	Greenstone, Llc	2001-02-05	Not applicable	US
Ziprasidone	Capsule	20 mg/1	Oral	Remedy Repack	2012-08-13	2017-08-09	US
Ziprasidone	Capsule	20 mg/1	Oral	Greenstone, Llc	2001-02-05	Not applicable	US
Ziprasidone	Capsule	40 mg/1	Oral	Avera Mc Kennan Hospital	2016-02-09	Not applicable	US
Ziprasidone	Capsule	40 mg/1	Oral	Remedy Repack	2013-05-02	2017-02-15	US
Ziprasidone	Capsule	80 mg/1	Oral	Greenstone, Llc	2001-02-05	Not applicable	US
Ziprasidone	Capsule	40 mg/1	Oral	Greenstone, Llc	2001-02-05	Not applicable	US
Ziprasidone	Capsule	80 mg/1	Oral	Remedy Repack	2013-01-08	2017-02-22	US

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Mc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation	2012-03-02	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Apotex Corporation	2012-05-14	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Blue Point Laboratories	2014-02-26	Not applicable	US
Ziprasidone hydrochloride	Capsule	20 mg/1	Oral	Wockhardt	2012-09-01	Not applicable	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	TYA Pharmaceuticals	2012-03-02	Not applicable	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Lupin Pharmaceuticals	2012-03-02	Not applicable	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Golden State Medical Supply	2012-05-14	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Unit Dose Services	2012-03-02	Not applicable	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Remedy Repack	2016-02-10	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	A S Medication Solutions	2012-05-14	2017-06-20	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2012-03-02	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	bryant ranch prepack	2012-05-14	Not applicable	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Rebel Distributors	2012-03-02	Not applicable	US
Ziprasidone hydrochloride	Capsule	20 mg/1	Oral	Wockhardt	2012-09-01	Not applicable	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Lupin Pharmaceuticals	2012-03-02	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Remedy Repack	2016-07-25	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Clinical Solutions Wholsesale	2012-05-14	Not applicable	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Major	2012-03-15	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Cardinal Health	2012-03-15	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Sandoz	2013-02-13	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Golden State Medical Supply	2012-05-14	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Mylan Institutional	2014-09-30	Not applicable	US
Ziprasidone hydrochloride	Capsule	80 mg/1	Oral	Wockhardt	2012-09-01	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Lupin Pharmaceuticals	2012-03-02	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Mc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation	2012-03-02	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Remedy Repack	2016-02-10	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Rebel Distributors	2012-03-02	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Cardinal Health	2013-07-02	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Remedy Repack	2014-04-25	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Macleods Pharmaceuticals Limited	2017-02-18	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Dr Reddy's Laboratories	2012-03-02	Not applicable	US
Ziprasidone hydrochloride	Capsule	80 mg/1	Oral	Wockhardt	2012-09-01	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	TYA Pharmaceuticals	2013-02-13	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Remedy Repack	2014-03-03	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Amerincan Health Packaging	2014-11-15	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Apotex Corporation	2012-05-14	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Aurobindo Pharma	2016-12-27	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Blue Point Laboratories	2014-02-26	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Mylan Pharmaceuticals	2014-06-24	2018-02-28	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Macleods Pharmaceuticals Limited	2017-02-18	Not applicable	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Dr Reddy's Laboratories	2012-03-02	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Proficient Rx LP	2012-05-14	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Lupin Pharmaceuticals	2012-03-02	Not applicable	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Remedy Repack	2014-11-11	2017-08-29	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Amerincan Health Packaging	2014-11-15	Not applicable	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Aurobindo Pharma	2016-12-27	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Major	2012-03-15	Not applicable	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Mylan Institutional	2014-09-30	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Rebel Distributors	2012-03-02	Not applicable	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Cardinal Health	2012-03-15	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Mc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation	2012-03-02	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Apotex Corporation	2012-05-14	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Blue Point Laboratories	2014-02-26	Not applicable	US
Ziprasidone hydrochloride	Capsule	40 mg/1	Oral	Wockhardt	2012-09-01	Not applicable	US
Ziprasidone hydrochloride	Capsule	60 mg/1	Oral	TYA Pharmaceuticals	2012-09-01	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Remedy Repack	2013-02-08	2016-10-13	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Unit Dose Services	2012-05-14	Not applicable	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Remedy Repack	2016-08-31	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Remedy Repack	2016-02-25	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Avera Mc Kennan Hospital	2016-07-07	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Sandoz	2013-02-13	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Golden State Medical Supply	2012-05-14	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Remedy Repack	2013-02-08	2016-10-13	US
Ziprasidone hydrochloride	Capsule	40 mg/1	Oral	Wockhardt	2012-09-01	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Lupin Pharmaceuticals	2012-03-02	Not applicable	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Remedy Repack	2016-08-19	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Clinical Solutions Wholsesale	2012-05-14	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Remedy Repack	2014-10-21	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Amerincan Health Packaging	2014-11-15	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Aurobindo Pharma	2016-12-27	Not applicable	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Sandoz	2013-02-13	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Mylan Institutional	2014-09-30	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Mylan Pharmaceuticals	2014-06-24	2017-07-31	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Macleods Pharmaceuticals Limited	2017-02-18	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Dr Reddy's Laboratories	2012-03-02	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Proficient Rx LP	2013-02-13	Not applicable	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	TYA Pharmaceuticals	2013-02-13	Not applicable	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Mylan Pharmaceuticals	2014-06-24	2018-06-30	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	A S Medication Solutions	2012-05-14	2017-06-20	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	bryant ranch prepack	2012-05-14	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Proficient Rx LP	2012-05-14	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Lupin Pharmaceuticals	2012-03-02	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Remedy Repack	2016-07-25	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Clinical Solutions Wholsesale	2012-05-14	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Major	2012-03-15	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Cardinal Health	2012-03-15	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Lupin Pharmaceuticals	2012-03-02	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Remedy Repack	2014-06-23	2017-12-12	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Clinical Solutions Wholsesale	2012-05-14	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Rebel Distributors	2012-03-02	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Cardinal Health	2012-03-15	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Mc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation	2012-03-02	Not applicable	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Apotex Corporation	2012-05-14	Not applicable	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Blue Point Laboratories	2014-02-26	Not applicable	US
Ziprasidone hydrochloride	Capsule	60 mg/1	Oral	Wockhardt	2012-09-01	Not applicable	US
Ziprasidone hydrochloride	Capsule	80 mg/1	Oral	TYA Pharmaceuticals	2012-09-01	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Remedy Repack	2012-03-29	2017-03-11	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	A S Medication Solutions	2012-05-14	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Remedy Repack	2016-08-31	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Remedy Repack	2016-03-01	Not applicable	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Avera Mc Kennan Hospital	2016-07-18	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Sandoz	2013-02-13	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Golden State Medical Supply	2012-05-14	Not applicable	US
Ziprasidone Hydrochloride	Capsule	80 mg/1	Oral	Remedy Repack	2013-02-15	2016-10-13	US
Ziprasidone hydrochloride	Capsule	60 mg/1	Oral	Wockhardt	2012-09-01	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Dr Reddy's Laboratories	2012-03-02	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Proficient Rx LP	2012-05-14	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Lupin Pharmaceuticals	2012-03-02	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Remedy Repack	2014-10-30	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Amerincan Health Packaging	2014-11-15	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Aurobindo Pharma	2016-12-27	Not applicable	US
Ziprasidone Hydrochloride	Capsule	20 mg/1	Oral	Major	2012-03-15	Not applicable	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Mylan Institutional	2014-09-30	Not applicable	US
Ziprasidone Hydrochloride	Capsule	40 mg/1	Oral	Mylan Pharmaceuticals	2014-06-24	2018-02-28	US
Ziprasidone Hydrochloride	Capsule	60 mg/1	Oral	Macleods Pharmaceuticals Limited	2017-02-18	Not applicable	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Not Available

Brand mixtures

Not Available

Categories

UNII

6UKA5VEJ6X

CAS number

146939-27-7

Weight

Average: 412.936
Monoisotopic: 412.112459711

Chemical Formula

C₂₁H₂₁ClN₄OS

InChI Key

MVWVFYHBGMAFLY-UHFFFAOYSA-N

InChI

InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)

IUPAC Name

5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-2,3-dihydro-1H-indol-2-one

SMILES

ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1

Pharmacology

Indication

For the treatment of schizophrenia and related psychotic disorders.

Structured Indications

Pharmacodynamics

Ziprasidone is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Ziprasidone is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Ziprasidone acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of Ziprasidone. Ziprasidone's antagonism of muscarinic M1-5 receptors may explain its anticholinergic effects. Ziprasidone's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Ziprasidone's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug. Ziprasidone functions as an antagonist at the Dopamine D2 , 5HT-2A , and 5HT-1D receptors, and as an agonist at the 5HT-1A receptor. Ziprasidone also inhibits synaptic reuptake of serotonin and norepinephrine.

Mechanism of action

Ziprasidone's antipsychotic activity is likely due to a combination of its antagonistic function at D2 receptors in the mesolimbic pathways and at 5HT2A receptors in the frontal cortex. Alleviation of positive symptoms is due to antagonism at D2 receptors while relief of negative symptoms are due to 5HT2A antagonism.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
D(2) dopamine receptor	Protein	yes	antagonist	Human	P14416	details
5-hydroxytryptamine receptor 2A	Protein	yes	antagonist	Human	P28223	details
D(1A) dopamine receptor	Protein	unknown	antagonist	Human	P21728	details
D(1B) dopamine receptor	Protein	unknown	antagonist	Human	P21918	details
D(3) dopamine receptor	Protein	unknown	antagonist	Human	P35462	details
D(4) dopamine receptor	Protein	unknown	antagonist	Human	P21917	details
5-hydroxytryptamine receptor 1A	Protein	unknown	agonist	Human	P08908	details
5-hydroxytryptamine receptor 1B	Protein	unknown	antagonist	Human	P28222	details
5-hydroxytryptamine receptor 1D	Protein	unknown	antagonist	Human	P28221	details
5-hydroxytryptamine receptor 1E	Protein	unknown	antagonist	Human	P28566	details
5-hydroxytryptamine receptor 2C	Protein	unknown	antagonist	Human	P28335	details
5-hydroxytryptamine receptor 3A	Protein	unknown	antagonist	Human	P46098	details
5-hydroxytryptamine receptor 6	Protein	unknown	antagonist	Human	P50406	details
5-hydroxytryptamine receptor 7	Protein	unknown	antagonist	Human	P34969	details
Histamine H1 receptor	Protein	no	antagonist	Human	P35367	details
Alpha-1A adrenergic receptor	Protein	no	antagonist	Human	P35348	details
Alpha-1B adrenergic receptor	Protein	no	antagonist	Human	P35368	details
Alpha-2A adrenergic receptor	Protein	no	antagonist	Human	P08913	details
Alpha-2B adrenergic receptor	Protein	no	antagonist	Human	P18089	details
Alpha-2C adrenergic receptor	Protein	no	antagonist	Human	P18825	details
Muscarinic acetylcholine receptor M1	Protein	no	antagonist	Human	P11229	details
Muscarinic acetylcholine receptor M2	Protein	no	antagonist	Human	P08172	details
Muscarinic acetylcholine receptor M3	Protein	no	antagonist	Human	P20309	details
Muscarinic acetylcholine receptor M4	Protein	no	antagonist	Human	P08173	details
Muscarinic acetylcholine receptor M5	Protein	no	antagonist	Human	P08912	details

Absorption

~60%

Volume of distribution

1.5 L/kg

Protein binding

99%

Metabolism

Hepatic

Substrate	Enzymes	Product
Ziprasidone	Cytochrome P450 3A4	benzisothiazole piperazine	Details

Route of elimination

Ziprasidone is extensively metabolized after oral administration with only a small amount excreted in the urine (<1%) or feces (<4%) as unchanged drug. Approximately 20% of the dose is excreted in the urine, with approximately 66% being eliminated in the feces.

Half life

7 hours

Clearance

7.5 mL/min/kg

Toxicity

Not Available

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
2,4-thiazolidinedione	The therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Ziprasidone.	Investigational
2,5-Dimethoxy-4-ethylamphetamine	Ziprasidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.	Experimental, Illicit
3,4-Methylenedioxyamphetamine	Ziprasidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.	Experimental, Illicit
3,4-Methylenedioxymethamphetamine	Ziprasidone may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.	Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine	Ziprasidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.	Experimental, Illicit
4-Methoxyamphetamine	The metabolism of 4-Methoxyamphetamine can be decreased when combined with Ziprasidone.	Experimental, Illicit
7-Nitroindazole	The risk or severity of adverse effects can be increased when Ziprasidone is combined with 7-Nitroindazole.	Experimental
Abiraterone	The serum concentration of Ziprasidone can be increased when it is combined with Abiraterone.	Approved
Acarbose	The therapeutic efficacy of Acarbose can be decreased when used in combination with Ziprasidone.	Approved, Investigational
Acenocoumarol	The metabolism of Acenocoumarol can be decreased when combined with Ziprasidone.	Approved
Acepromazine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Acepromazine.	Approved, Vet Approved
Aceprometazine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Aceprometazine.	Approved
Acetaminophen	The metabolism of Acetaminophen can be decreased when combined with Ziprasidone.	Approved
Acetohexamide	The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ziprasidone.	Withdrawn
Acetylcholine	The metabolism of Acetylcholine can be decreased when combined with Ziprasidone.	Approved
Adinazolam	The metabolism of Adinazolam can be decreased when combined with Ziprasidone.	Approved
Adipiplon	The risk or severity of adverse effects can be increased when Ziprasidone is combined with adipiplon.	Investigational
Agomelatine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Agomelatine.	Approved, Investigational
AICA ribonucleotide	The therapeutic efficacy of Aicar can be decreased when used in combination with Ziprasidone.	Experimental
Ajmaline	The metabolism of Ajmaline can be decreased when combined with Ziprasidone.	Approved
Albendazole	The metabolism of Albendazole can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Alclometasone	The metabolism of Alclometasone can be decreased when combined with Ziprasidone.	Approved
Alfaxalone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Alfaxalone.	Vet Approved
Alfentanil	The metabolism of Alfentanil can be decreased when combined with Ziprasidone.	Approved, Illicit
Alfuzosin	Alfuzosin may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Aliskiren	The metabolism of Aliskiren can be decreased when combined with Ziprasidone.	Approved, Investigational
Allopregnanolone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Sage 547.	Investigational
Allylestrenol	The metabolism of Allylestrenol can be decreased when combined with Ziprasidone.	Approved
Almotriptan	The metabolism of Almotriptan can be decreased when combined with Ziprasidone.	Approved, Investigational
Alogliptin	The metabolism of Alogliptin can be decreased when combined with Ziprasidone.	Approved
Alosetron	The metabolism of Alosetron can be decreased when combined with Ziprasidone.	Approved, Withdrawn
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Alphacetylmethadol.	Experimental, Illicit
Alprazolam	The metabolism of Alprazolam can be decreased when combined with Ziprasidone.	Approved, Illicit, Investigational
Alprenolol	The metabolism of Alprenolol can be decreased when combined with Ziprasidone.	Approved, Withdrawn
Amantadine	Amantadine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Ambrisentan	The metabolism of Ambrisentan can be decreased when combined with Ziprasidone.	Approved, Investigational
Ambroxol	The metabolism of Ambroxol can be decreased when combined with Ziprasidone.	Approved
Aminophenazone	The metabolism of Aminophenazone can be decreased when combined with Ziprasidone.	Approved, Withdrawn
Aminophylline	The metabolism of Aminophylline can be decreased when combined with Ziprasidone.	Approved
Amiodarone	Ziprasidone may increase the QTc-prolonging activities of Amiodarone.	Approved, Investigational
Amisulpride	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Amisulpride.	Approved, Investigational
Amitriptyline	Amitriptyline may increase the QTc-prolonging activities of Ziprasidone.	Approved
Amlodipine	The metabolism of Amlodipine can be decreased when combined with Ziprasidone.	Approved
Amobarbital	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Amobarbital.	Approved, Illicit
Amoxapine	Amoxapine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Amperozide	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Amperozide.	Experimental
Amphetamine	The metabolism of Amphetamine can be decreased when combined with Ziprasidone.	Approved, Illicit
Amprenavir	The metabolism of Amprenavir can be decreased when combined with Ziprasidone.	Approved
Amsacrine	The metabolism of Amsacrine can be decreased when combined with Ziprasidone.	Approved
Anagrelide	Ziprasidone may increase the QTc-prolonging activities of Anagrelide.	Approved
Antipyrine	The metabolism of Antipyrine can be decreased when combined with Ziprasidone.	Approved
Apixaban	The serum concentration of Apixaban can be increased when it is combined with Ziprasidone.	Approved
Apomorphine	Apomorphine may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Apremilast	The metabolism of Apremilast can be decreased when combined with Ziprasidone.	Approved, Investigational
Aprepitant	The serum concentration of Ziprasidone can be increased when it is combined with Aprepitant.	Approved, Investigational
Aprindine	The metabolism of Aprindine can be decreased when combined with Ziprasidone.	Approved
Arformoterol	Arformoterol may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Argatroban	The metabolism of Argatroban can be decreased when combined with Ziprasidone.	Approved, Investigational
Aripiprazole	The serum concentration of Aripiprazole can be increased when it is combined with Ziprasidone.	Approved, Investigational
Arsenic trioxide	Ziprasidone may increase the QTc-prolonging activities of Arsenic trioxide.	Approved, Investigational
Artemether	Ziprasidone may increase the QTc-prolonging activities of Artemether.	Approved
Articaine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Articaine.	Approved
Asenapine	Ziprasidone may increase the QTc-prolonging activities of Asenapine.	Approved
Astemizole	The metabolism of Astemizole can be decreased when combined with Ziprasidone.	Approved, Withdrawn
Atazanavir	The metabolism of Ziprasidone can be decreased when combined with Atazanavir.	Approved, Investigational
Atomoxetine	Atomoxetine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Atorvastatin	The metabolism of Atorvastatin can be decreased when combined with Ziprasidone.	Approved
Avanafil	The serum concentration of Avanafil can be increased when it is combined with Ziprasidone.	Approved
Axitinib	The metabolism of Axitinib can be decreased when combined with Ziprasidone.	Approved, Investigational
Azaperone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Azaperone.	Vet Approved
Azelastine	Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.	Approved
Azelastine	The metabolism of Azelastine can be decreased when combined with Ziprasidone.	Approved
Azithromycin	Azithromycin may increase the QTc-prolonging activities of Ziprasidone.	Approved
Baclofen	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Baclofen.	Approved
Balaglitazone	The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Ziprasidone.	Investigational
Banoxantrone	The metabolism of Banoxantrone can be decreased when combined with Ziprasidone.	Investigational
Barbital	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Barbital.	Illicit
Bedaquiline	Bedaquiline may increase the QTc-prolonging activities of Ziprasidone.	Approved
Benperidol	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Benperidol.	Investigational
Benzatropine	The metabolism of Benzatropine can be decreased when combined with Ziprasidone.	Approved
Benzocaine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Benzocaine.	Approved
Benzphetamine	The metabolism of Benzphetamine can be decreased when combined with Ziprasidone.	Approved, Illicit
Benzyl alcohol	The metabolism of Benzyl alcohol can be decreased when combined with Ziprasidone.	Approved
Bepridil	The metabolism of Bepridil can be decreased when combined with Ziprasidone.	Approved, Withdrawn
Betaxolol	The metabolism of Betaxolol can be decreased when combined with Ziprasidone.	Approved
Bexarotene	The serum concentration of Ziprasidone can be decreased when it is combined with Bexarotene.	Approved, Investigational
Bezafibrate	The metabolism of Bezafibrate can be decreased when combined with Ziprasidone.	Approved
Bicalutamide	The metabolism of Bicalutamide can be decreased when combined with Ziprasidone.	Approved
Bisoprolol	The metabolism of Bisoprolol can be decreased when combined with Ziprasidone.	Approved
Boceprevir	The metabolism of Ziprasidone can be decreased when combined with Boceprevir.	Withdrawn
Bortezomib	Bortezomib may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Bosentan	The serum concentration of Bosentan can be increased when it is combined with Ziprasidone.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Ziprasidone.	Approved
Brentuximab vedotin	The metabolism of Brentuximab vedotin can be decreased when combined with Ziprasidone.	Approved
Brexpiprazole	The serum concentration of Brexpiprazole can be increased when it is combined with Ziprasidone.	Approved
Brimonidine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Brimonidine.	Approved
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.	Approved
Brinzolamide	The metabolism of Brinzolamide can be decreased when combined with Ziprasidone.	Approved
Bromazepam	The metabolism of Bromazepam can be decreased when combined with Ziprasidone.	Approved, Illicit
Bromocriptine	The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Ziprasidone.	Approved, Investigational
Brompheniramine	The metabolism of Brompheniramine can be decreased when combined with Ziprasidone.	Approved
Brotizolam	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Brotizolam.	Approved, Withdrawn
Budesonide	The serum concentration of Budesonide can be increased when it is combined with Ziprasidone.	Approved
Budesonide	The metabolism of Budesonide can be decreased when combined with Ziprasidone.	Approved
Buformin	The therapeutic efficacy of Buformin can be decreased when used in combination with Ziprasidone.	Withdrawn
Bufuralol	The metabolism of Bufuralol can be decreased when combined with Ziprasidone.	Experimental, Investigational
Bupivacaine	The metabolism of Bupivacaine can be decreased when combined with Ziprasidone.	Approved, Investigational
Buprenorphine	Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Bupropion	The metabolism of Bupropion can be decreased when combined with Ziprasidone.	Approved
Buserelin	Buserelin may increase the QTc-prolonging activities of Ziprasidone.	Approved
Buspirone	The metabolism of Buspirone can be decreased when combined with Ziprasidone.	Approved, Investigational
Busulfan	The metabolism of Busulfan can be decreased when combined with Ziprasidone.	Approved, Investigational
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Ziprasidone.	Approved, Illicit
Butacaine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Butacaine.	Vet Approved
Butalbital	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Butalbital.	Approved, Illicit
Butamben	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Butamben.	Approved
Butethal	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Butethal.	Approved, Illicit
Butorphanol	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Butorphanol.	Approved, Illicit, Vet Approved
Cabazitaxel	The metabolism of Cabazitaxel can be decreased when combined with Ziprasidone.	Approved
Cabergoline	The metabolism of Cabergoline can be decreased when combined with Ziprasidone.	Approved
Cabozantinib	The metabolism of Cabozantinib can be decreased when combined with Ziprasidone.	Approved
Caffeine	The metabolism of Caffeine can be decreased when combined with Ziprasidone.	Approved
Calcitriol	The metabolism of Calcitriol can be decreased when combined with Ziprasidone.	Approved, Nutraceutical
Canagliflozin	The metabolism of Canagliflozin can be decreased when combined with Ziprasidone.	Approved
Captopril	The metabolism of Captopril can be decreased when combined with Ziprasidone.	Approved
Carbamazepine	The serum concentration of Ziprasidone can be decreased when it is combined with Carbamazepine.	Approved, Investigational
Carbinoxamine	The metabolism of Carbinoxamine can be decreased when combined with Ziprasidone.	Approved
Carfentanil	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Carfentanil.	Illicit, Vet Approved
Cariprazine	The metabolism of Cariprazine can be decreased when combined with Ziprasidone.	Approved
Carisoprodol	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Carisoprodol.	Approved
Carteolol	The metabolism of Carteolol can be decreased when combined with Ziprasidone.	Approved
Carvedilol	The metabolism of Carvedilol can be decreased when combined with Ziprasidone.	Approved, Investigational
Castanospermine	The therapeutic efficacy of Castanospermine can be decreased when used in combination with Ziprasidone.	Experimental
Celecoxib	The metabolism of Celecoxib can be decreased when combined with Ziprasidone.	Approved, Investigational
Celiprolol	The metabolism of Celiprolol can be decreased when combined with Ziprasidone.	Approved, Investigational
Cephalexin	The metabolism of Cephalexin can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Ceritinib	The serum concentration of Ziprasidone can be increased when it is combined with Ceritinib.	Approved
Cerivastatin	The metabolism of Cerivastatin can be decreased when combined with Ziprasidone.	Withdrawn
Cetirizine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Cetirizine.	Approved
Cevimeline	The metabolism of Cevimeline can be decreased when combined with Ziprasidone.	Approved
Chenodeoxycholic acid	The metabolism of Chenodeoxycholic acid can be decreased when combined with Ziprasidone.	Approved
Chloral hydrate	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Chloral hydrate.	Approved, Illicit, Vet Approved
Chlordiazepoxide	The metabolism of Chlordiazepoxide can be decreased when combined with Ziprasidone.	Approved, Illicit
Chlormezanone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Chlormezanone.	Approved, Withdrawn
Chloroprocaine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Chloroprocaine.	Approved
Chloroquine	Chloroquine may increase the QTc-prolonging activities of Ziprasidone.	Approved, Vet Approved
Chlorphenamine	The metabolism of Chlorphenamine can be decreased when combined with Ziprasidone.	Approved
Chlorphentermine	Ziprasidone may decrease the stimulatory activities of Chlorphentermine.	Illicit, Withdrawn
Chlorpromazine	Chlorpromazine may increase the QTc-prolonging activities of Ziprasidone.	Approved, Vet Approved
Chlorpropamide	The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Ziprasidone.	Approved
Chlorprothixene	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Chlorprothixene.	Approved, Withdrawn
Chlorzoxazone	The metabolism of Chlorzoxazone can be decreased when combined with Ziprasidone.	Approved
Cholecalciferol	The metabolism of Cholecalciferol can be decreased when combined with Ziprasidone.	Approved, Nutraceutical
Ciclesonide	The metabolism of Ciclesonide can be decreased when combined with Ziprasidone.	Approved, Investigational
Ciglitazone	The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Ziprasidone.	Experimental
Cilostazol	The serum concentration of Cilostazol can be increased when it is combined with Ziprasidone.	Approved
Cinacalcet	The metabolism of Cinacalcet can be decreased when combined with Ziprasidone.	Approved
Cinchocaine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Cinchocaine.	Approved, Vet Approved
Cinnarizine	The metabolism of Cinnarizine can be decreased when combined with Ziprasidone.	Approved
Ciprofloxacin	Ciprofloxacin may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Cisapride	Ziprasidone may increase the QTc-prolonging activities of Cisapride.	Approved, Investigational, Withdrawn
Citalopram	Citalopram may increase the QTc-prolonging activities of Ziprasidone.	Approved
Clarithromycin	Clarithromycin may increase the QTc-prolonging activities of Ziprasidone.	Approved
Clemastine	The metabolism of Ziprasidone can be decreased when combined with Clemastine.	Approved
Clevidipine	The metabolism of Clevidipine can be decreased when combined with Ziprasidone.	Approved
Clidinium	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Clidinium.	Approved
Clindamycin	The metabolism of Clindamycin can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Clobazam	The metabolism of Clobazam can be decreased when combined with Ziprasidone.	Approved, Illicit
Clofazimine	The metabolism of Clofazimine can be decreased when combined with Ziprasidone.	Approved, Investigational
Clofibrate	The metabolism of Clofibrate can be decreased when combined with Ziprasidone.	Approved
clomethiazole	The metabolism of clomethiazole can be decreased when combined with Ziprasidone.	Investigational
Clomipramine	Clomipramine may increase the QTc-prolonging activities of Ziprasidone.	Approved, Vet Approved
Clonazepam	The metabolism of Clonazepam can be decreased when combined with Ziprasidone.	Approved, Illicit
Clonidine	The metabolism of Clonidine can be decreased when combined with Ziprasidone.	Approved
Clopidogrel	The metabolism of Clopidogrel can be decreased when combined with Ziprasidone.	Approved, Nutraceutical
Clorazepate	The metabolism of Clorazepate can be decreased when combined with Ziprasidone.	Approved, Illicit
Clotiazepam	The metabolism of Clotiazepam can be decreased when combined with Ziprasidone.	Approved, Illicit
Clotrimazole	The metabolism of Ziprasidone can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	Clozapine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Cobicistat	The metabolism of Ziprasidone can be decreased when combined with Cobicistat.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Ziprasidone.	Approved
Cocaine	The metabolism of Cocaine can be decreased when combined with Ziprasidone.	Approved, Illicit
Codeine	The therapeutic efficacy of Codeine can be decreased when used in combination with Ziprasidone.	Approved, Illicit
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Ziprasidone.	Approved
Conivaptan	The serum concentration of Ziprasidone can be increased when it is combined with Conivaptan.	Approved, Investigational
Conjugated estrogens	The metabolism of Conjugated Equine Estrogens can be decreased when combined with Ziprasidone.	Approved
Cortisone acetate	The metabolism of Cortisone acetate can be decreased when combined with Ziprasidone.	Approved
Crizotinib	Crizotinib may increase the QTc-prolonging activities of Ziprasidone.	Approved
Cyclizine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Cyclizine.	Approved
Cyclobenzaprine	The metabolism of Cyclobenzaprine can be decreased when combined with Ziprasidone.	Approved
Cyclophosphamide	The metabolism of Cyclophosphamide can be decreased when combined with Ziprasidone.	Approved, Investigational
Cyclosporine	The metabolism of Cyclosporine can be decreased when combined with Ziprasidone.	Approved, Investigational, Vet Approved
Cyproheptadine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Cyproheptadine.	Approved
Cyproterone acetate	The serum concentration of Ziprasidone can be decreased when it is combined with Cyproterone acetate.	Approved, Investigational
Cytarabine	The metabolism of Cytarabine can be decreased when combined with Ziprasidone.	Approved, Investigational
Dabrafenib	The serum concentration of Ziprasidone can be decreased when it is combined with Dabrafenib.	Approved
Daclatasvir	The metabolism of Daclatasvir can be decreased when combined with Ziprasidone.	Approved
Dantrolene	The metabolism of Dantrolene can be decreased when combined with Ziprasidone.	Approved
Dapagliflozin	The metabolism of Dapagliflozin can be decreased when combined with Ziprasidone.	Approved
Dapiprazole	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dapiprazole.	Approved
Dapoxetine	The serum concentration of Dapoxetine can be increased when it is combined with Ziprasidone.	Investigational
Dapsone	The metabolism of Dapsone can be decreased when combined with Ziprasidone.	Approved, Investigational
Darifenacin	The metabolism of Darifenacin can be decreased when combined with Ziprasidone.	Approved, Investigational
Darunavir	The metabolism of Ziprasidone can be decreased when combined with Darunavir.	Approved
Dasabuvir	The metabolism of Dasabuvir can be decreased when combined with Ziprasidone.	Approved
Dasatinib	The serum concentration of Ziprasidone can be increased when it is combined with Dasatinib.	Approved, Investigational
Daunorubicin	The metabolism of Daunorubicin can be decreased when combined with Ziprasidone.	Approved
Debrisoquin	The metabolism of Debrisoquin can be decreased when combined with Ziprasidone.	Approved
Deferasirox	The serum concentration of Ziprasidone can be decreased when it is combined with Deferasirox.	Approved, Investigational
Degarelix	Degarelix may increase the QTc-prolonging activities of Ziprasidone.	Approved
Delavirdine	The metabolism of Delavirdine can be decreased when combined with Ziprasidone.	Approved
Deoxyspergualin	The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Ziprasidone.	Investigational
Deramciclane	The risk or severity of adverse effects can be increased when Ziprasidone is combined with deramciclane.	Investigational
Desflurane	Desflurane may increase the QTc-prolonging activities of Ziprasidone.	Approved
Desipramine	Desipramine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Desloratadine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Desloratadine.	Approved, Investigational
Desvenlafaxine	The metabolism of Desvenlafaxine can be decreased when combined with Ziprasidone.	Approved
Detomidine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Detomidine.	Vet Approved
Dexamethasone	The serum concentration of Ziprasidone can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexbrompheniramine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dexbrompheniramine.	Approved
Dexfenfluramine	The metabolism of Dexfenfluramine can be decreased when combined with Ziprasidone.	Approved, Illicit, Withdrawn
Dexmedetomidine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dexmedetomidine.	Approved, Vet Approved
Dexmethylphenidate	The metabolism of Dexmethylphenidate can be decreased when combined with Ziprasidone.	Approved
Dextroamphetamine	The metabolism of Dextroamphetamine can be decreased when combined with Ziprasidone.	Approved, Illicit
Dextromethorphan	The metabolism of Dextromethorphan can be decreased when combined with Ziprasidone.	Approved
Dextromoramide	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dextromoramide.	Experimental, Illicit
Dextropropoxyphene	The metabolism of Dextropropoxyphene can be decreased when combined with Ziprasidone.	Approved, Illicit, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dezocine.	Approved
Diazepam	The metabolism of Diazepam can be decreased when combined with Ziprasidone.	Approved, Illicit, Vet Approved
Diclofenac	The metabolism of Diclofenac can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Diethylpropion	Ziprasidone may decrease the stimulatory activities of Diethylpropion.	Approved, Illicit
Difenoxin	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Difenoxin.	Approved, Illicit
Digitoxin	The metabolism of Digitoxin can be decreased when combined with Ziprasidone.	Approved
Digoxin	The metabolism of Digoxin can be decreased when combined with Ziprasidone.	Approved
Dihydrocodeine	The metabolism of Dihydrocodeine can be decreased when combined with Ziprasidone.	Approved, Illicit
Dihydroergotamine	The metabolism of Dihydroergotamine can be decreased when combined with Ziprasidone.	Approved
Dihydroetorphine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dihydroetorphine.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dihydromorphine.	Experimental, Illicit
Diltiazem	The metabolism of Diltiazem can be decreased when combined with Ziprasidone.	Approved
Dimenhydrinate	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dimenhydrinate.	Approved
Diphenhydramine	Diphenhydramine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Diphenoxylate	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Diphenoxylate.	Approved, Illicit
Disopyramide	Ziprasidone may increase the QTc-prolonging activities of Disopyramide.	Approved
Disulfiram	The metabolism of Disulfiram can be decreased when combined with Ziprasidone.	Approved
Docetaxel	The metabolism of Docetaxel can be decreased when combined with Ziprasidone.	Approved, Investigational
Dofetilide	The serum concentration of Dofetilide can be increased when it is combined with Ziprasidone.	Approved
Dolasetron	Dolasetron may increase the QTc-prolonging activities of Ziprasidone.	Approved
Domperidone	The serum concentration of Domperidone can be increased when it is combined with Ziprasidone.	Approved, Investigational, Vet Approved
Donepezil	The metabolism of Donepezil can be decreased when combined with Ziprasidone.	Approved
Dopamine	The metabolism of Dopamine can be decreased when combined with Ziprasidone.	Approved
Doramectin	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Doramectin.	Vet Approved
Dorzolamide	The metabolism of Dorzolamide can be decreased when combined with Ziprasidone.	Approved
Doxazosin	The metabolism of Doxazosin can be decreased when combined with Ziprasidone.	Approved
Doxepin	Doxepin may increase the QTc-prolonging activities of Ziprasidone.	Approved
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Ziprasidone.	Approved, Investigational
Doxorubicin	The metabolism of Doxorubicin can be decreased when combined with Ziprasidone.	Approved, Investigational
Doxycycline	The metabolism of Ziprasidone can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.	Approved, Vet Approved
DPDPE	The risk or severity of adverse effects can be increased when Ziprasidone is combined with DPDPE.	Investigational
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.	Approved, Illicit
Dronedarone	Ziprasidone may increase the QTc-prolonging activities of Dronedarone.	Approved
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.	Approved, Vet Approved
Drotebanol	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Drotebanol.	Experimental, Illicit
Dulaglutide	The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ziprasidone.	Approved
Duloxetine	The metabolism of Duloxetine can be decreased when combined with Ziprasidone.	Approved
Dutasteride	The metabolism of Dutasteride can be decreased when combined with Ziprasidone.	Approved, Investigational
Dyclonine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dyclonine.	Approved
Ecgonine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ecgonine.	Experimental, Illicit
Ecopipam	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ecopipam.	Investigational
Efavirenz	The serum concentration of Ziprasidone can be decreased when it is combined with Efavirenz.	Approved, Investigational
Eletriptan	The serum concentration of Eletriptan can be increased when it is combined with Ziprasidone.	Approved, Investigational
Eliglustat	The serum concentration of Eliglustat can be increased when it is combined with Ziprasidone.	Approved
Eltanolone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Pregnanolone.	Investigational
Elvitegravir	The metabolism of Elvitegravir can be decreased when combined with Ziprasidone.	Approved
Empagliflozin	The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ziprasidone.	Approved
Enalapril	The metabolism of Enalapril can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Encainide	The metabolism of Encainide can be decreased when combined with Ziprasidone.	Approved, Withdrawn
Enclomiphene	The metabolism of Enclomiphene can be decreased when combined with Ziprasidone.	Investigational
Enflurane	The risk or severity of adverse effects can be increased when Enflurane is combined with Ziprasidone.	Approved, Vet Approved
Entacapone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Entacapone.	Approved, Investigational
Enzalutamide	The serum concentration of Ziprasidone can be decreased when it is combined with Enzalutamide.	Approved
Epinastine	The metabolism of Epinastine can be decreased when combined with Ziprasidone.	Approved, Investigational
Eplerenone	The serum concentration of Eplerenone can be increased when it is combined with Ziprasidone.	Approved
Ergocalciferol	The metabolism of Ergocalciferol can be decreased when combined with Ziprasidone.	Approved, Nutraceutical
Ergoloid mesylate	The metabolism of Ergoloid mesylate can be decreased when combined with Ziprasidone.	Approved
Ergonovine	The metabolism of Ergonovine can be decreased when combined with Ziprasidone.	Approved
Ergotamine	The metabolism of Ergotamine can be decreased when combined with Ziprasidone.	Approved
Eribulin	Eribulin may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Erlotinib	The metabolism of Erlotinib can be decreased when combined with Ziprasidone.	Approved, Investigational
Erythromycin	Erythromycin may increase the QTc-prolonging activities of Ziprasidone.	Approved, Vet Approved
Escitalopram	Ziprasidone may increase the QTc-prolonging activities of Escitalopram.	Approved, Investigational
Eslicarbazepine acetate	The serum concentration of Ziprasidone can be decreased when it is combined with Eslicarbazepine acetate.	Approved
Esmirtazapine	The metabolism of Esmirtazapine can be decreased when combined with Ziprasidone.	Investigational
Esomeprazole	The metabolism of Esomeprazole can be decreased when combined with Ziprasidone.	Approved, Investigational
Estazolam	The metabolism of Estazolam can be decreased when combined with Ziprasidone.	Approved, Illicit
Estradiol	The metabolism of Estradiol can be decreased when combined with Ziprasidone.	Approved, Investigational, Vet Approved
Estradiol valerate/Dienogest	The metabolism of Estradiol valerate/Dienogest can be decreased when combined with Ziprasidone.	Approved
Estramustine	The metabolism of Estramustine can be decreased when combined with Ziprasidone.	Approved
Estrone	The metabolism of Estrone can be decreased when combined with Ziprasidone.	Approved
Estrone sulfate	The metabolism of Estrone sulfate can be decreased when combined with Ziprasidone.	Approved
Eszopiclone	The metabolism of Eszopiclone can be decreased when combined with Ziprasidone.	Approved
Ethanol	Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.	Approved
Ethchlorvynol	The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ziprasidone.	Approved, Illicit, Withdrawn
Ethinyl Estradiol	The metabolism of Ethinyl Estradiol can be decreased when combined with Ziprasidone.	Approved
Ethosuximide	The metabolism of Ethosuximide can be decreased when combined with Ziprasidone.	Approved
Ethotoin	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethotoin.	Approved
Ethyl carbamate	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethyl carbamate.	Withdrawn
Ethyl loflazepate	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethyl loflazepate.	Approved, Illicit
Ethylmorphine	The metabolism of Ethylmorphine can be decreased when combined with Ziprasidone.	Approved, Illicit
Etidocaine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Etidocaine.	Approved
Etifoxine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Etifoxine.	Withdrawn
Etizolam	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Etizolam.	Approved
Etomidate	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Etomidate.	Approved
Etonogestrel	The metabolism of Etonogestrel can be decreased when combined with Ziprasidone.	Approved, Investigational
Etoperidone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Etoperidone.	Approved
Etoposide	The metabolism of Etoposide can be decreased when combined with Ziprasidone.	Approved
Etoricoxib	The metabolism of Etoricoxib can be decreased when combined with Ziprasidone.	Approved, Investigational
Etorphine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Etorphine.	Illicit, Vet Approved
Etravirine	The serum concentration of Ziprasidone can be decreased when it is combined with Etravirine.	Approved
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Ziprasidone.	Approved
Exemestane	The metabolism of Exemestane can be decreased when combined with Ziprasidone.	Approved, Investigational
Exenatide	The therapeutic efficacy of Exenatide can be decreased when used in combination with Ziprasidone.	Approved, Investigational
Ezogabine	Ezogabine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Famciclovir	The metabolism of Famciclovir can be decreased when combined with Ziprasidone.	Approved
Famotidine	Famotidine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Felbamate	Felbamate may increase the QTc-prolonging activities of Ziprasidone.	Approved
Felodipine	The metabolism of Felodipine can be decreased when combined with Ziprasidone.	Approved, Investigational
Fencamfamine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Fencamfamine.	Approved, Illicit, Withdrawn
Fenofibrate	The metabolism of Fenofibrate can be decreased when combined with Ziprasidone.	Approved
Fentanyl	The serum concentration of Fentanyl can be increased when it is combined with Ziprasidone.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ziprasidone.	Approved
Fexofenadine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Fexofenadine.	Approved
Finasteride	The metabolism of Finasteride can be decreased when combined with Ziprasidone.	Approved
Fingolimod	Fingolimod may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Flecainide	Flecainide may increase the QTc-prolonging activities of Ziprasidone.	Approved, Withdrawn
Flibanserin	The serum concentration of Flibanserin can be increased when it is combined with Ziprasidone.	Approved
Fluconazole	Fluconazole may increase the QTc-prolonging activities of Ziprasidone.	Approved
Fludiazepam	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Fludiazepam.	Approved, Illicit
Flunarizine	The metabolism of Flunarizine can be decreased when combined with Ziprasidone.	Approved
Flunisolide	The metabolism of Flunisolide can be decreased when combined with Ziprasidone.	Approved, Investigational
Flunitrazepam	The metabolism of Flunitrazepam can be decreased when combined with Ziprasidone.	Approved, Illicit
Fluorometholone	The metabolism of Fluorometholone can be decreased when combined with Ziprasidone.	Approved
Fluoxetine	Fluoxetine may increase the QTc-prolonging activities of Ziprasidone.	Approved, Vet Approved
Flupentixol	Ziprasidone may increase the QTc-prolonging activities of Flupentixol.	Approved, Withdrawn
Fluphenazine	The metabolism of Fluphenazine can be decreased when combined with Ziprasidone.	Approved
Flurazepam	The metabolism of Flurazepam can be decreased when combined with Ziprasidone.	Approved, Illicit
Fluspirilene	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Fluspirilene.	Approved
Flutamide	The metabolism of Flutamide can be decreased when combined with Ziprasidone.	Approved
Fluticasone furoate	The metabolism of Fluticasone furoate can be decreased when combined with Ziprasidone.	Approved
Fluticasone propionate	The metabolism of Fluticasone Propionate can be decreased when combined with Ziprasidone.	Approved
Fluvastatin	The metabolism of Fluvastatin can be decreased when combined with Ziprasidone.	Approved
Fluvoxamine	The metabolism of Ziprasidone can be decreased when combined with Fluvoxamine.	Approved, Investigational
Formoterol	Formoterol may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Fosamprenavir	The metabolism of Fosamprenavir can be decreased when combined with Ziprasidone.	Approved
Fosaprepitant	The serum concentration of Ziprasidone can be increased when it is combined with Fosaprepitant.	Approved
Foscarnet	Foscarnet may increase the QTc-prolonging activities of Ziprasidone.	Approved
Fosphenytoin	The metabolism of Ziprasidone can be increased when combined with Fosphenytoin.	Approved
Fospropofol	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Fospropofol.	Approved, Illicit
Frovatriptan	The risk or severity of adverse effects can be increased when Frovatriptan is combined with Ziprasidone.	Approved, Investigational
Fulvestrant	The metabolism of Fulvestrant can be decreased when combined with Ziprasidone.	Approved, Investigational
Fusidic Acid	The serum concentration of Ziprasidone can be increased when it is combined with Fusidic Acid.	Approved
Gabapentin	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Gabapentin.	Approved, Investigational
Gabapentin Enacarbil	The risk or severity of adverse effects can be increased when Ziprasidone is combined with gabapentin enacarbil.	Approved
Gadobenic acid	Gadobenic acid may increase the QTc-prolonging activities of Ziprasidone.	Approved
Galantamine	Galantamine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Gamma Hydroxybutyric Acid	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Gamma Hydroxybutyric Acid.	Approved, Illicit
Gefitinib	The metabolism of Gefitinib can be decreased when combined with Ziprasidone.	Approved, Investigational
Gemfibrozil	The metabolism of Gemfibrozil can be decreased when combined with Ziprasidone.	Approved
Gemifloxacin	Gemifloxacin may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Gepirone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Gepirone.	Investigational
Glibornuride	The therapeutic efficacy of Glibornuride can be decreased when used in combination with Ziprasidone.	Withdrawn
Gliclazide	The therapeutic efficacy of Gliclazide can be decreased when used in combination with Ziprasidone.	Approved
Glimepiride	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Ziprasidone.	Approved
Glipizide	The metabolism of Glipizide can be decreased when combined with Ziprasidone.	Approved
Gliquidone	The therapeutic efficacy of Gliquidone can be decreased when used in combination with Ziprasidone.	Approved
Glutethimide	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Glutethimide.	Approved, Illicit
Glyburide	The metabolism of Glyburide can be decreased when combined with Ziprasidone.	Approved
Goserelin	Goserelin may increase the QTc-prolonging activities of Ziprasidone.	Approved
Granisetron	Granisetron may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Grepafloxacin	The metabolism of Grepafloxacin can be decreased when combined with Ziprasidone.	Withdrawn
Guanfacine	The metabolism of Guanfacine can be decreased when combined with Ziprasidone.	Approved, Investigational
Gusperimus	The therapeutic efficacy of Gusperimus can be decreased when used in combination with Ziprasidone.	Investigational
Halazepam	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Halazepam.	Approved, Illicit, Withdrawn
Halofantrine	The serum concentration of Halofantrine can be increased when it is combined with Ziprasidone.	Approved
Haloperidol	Haloperidol may increase the QTc-prolonging activities of Ziprasidone.	Approved
Halothane	The metabolism of Halothane can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Heroin	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Heroin.	Approved, Illicit
Hexobarbital	The metabolism of Hexobarbital can be decreased when combined with Ziprasidone.	Approved
Histamine	The metabolism of Histamine Phosphate can be decreased when combined with Ziprasidone.	Approved, Investigational
Histrelin	Histrelin may increase the QTc-prolonging activities of Ziprasidone.	Approved
Hydrocodone	Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.	Approved, Illicit
Hydrocortisone	The metabolism of Hydrocortisone can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Hydromorphone	The metabolism of Hydromorphone can be decreased when combined with Ziprasidone.	Approved, Illicit
Hydroxyamphetamine	Ziprasidone may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.	Approved
Hydroxyprogesterone caproate	The metabolism of Hydroxyprogesterone caproate can be decreased when combined with Ziprasidone.	Approved
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.	Approved
Ibandronate	Ibandronate may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Ibrutinib	The serum concentration of Ibrutinib can be increased when it is combined with Ziprasidone.	Approved
Ibutilide	Ziprasidone may increase the QTc-prolonging activities of Ibutilide.	Approved
Idarubicin	The metabolism of Idarubicin can be decreased when combined with Ziprasidone.	Approved
Idelalisib	The serum concentration of Ziprasidone can be increased when it is combined with Idelalisib.	Approved
Ifosfamide	The serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Ziprasidone resulting in a loss in efficacy.	Approved
Iloperidone	Ziprasidone may increase the QTc-prolonging activities of Iloperidone.	Approved
Imatinib	The serum concentration of Imatinib can be increased when it is combined with Ziprasidone.	Approved
Imipramine	Imipramine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Imiquimod	The metabolism of Imiquimod can be decreased when combined with Ziprasidone.	Approved, Investigational
Indacaterol	Indacaterol may increase the QTc-prolonging activities of Ziprasidone.	Approved
Indalpine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Indalpine.	Investigational, Withdrawn
Indapamide	Indapamide may increase the QTc-prolonging activities of Ziprasidone.	Approved
Indinavir	The metabolism of Ziprasidone can be decreased when combined with Indinavir.	Approved
Insulin Aspart	The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Ziprasidone.	Approved
Insulin Detemir	The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Ziprasidone.	Approved
Insulin Glargine	The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ziprasidone.	Approved
Insulin Glulisine	The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Ziprasidone.	Approved
Insulin Lispro	The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ziprasidone.	Approved
Insulin Pork	The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Ziprasidone.	Approved
Ipratropium bromide	The metabolism of Ipratropium bromide can be decreased when combined with Ziprasidone.	Approved
Irinotecan	The metabolism of Irinotecan can be decreased when combined with Ziprasidone.	Approved, Investigational
Isavuconazonium	The metabolism of Isavuconazonium can be decreased when combined with Ziprasidone.	Approved, Investigational
Isocarboxazid	The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ziprasidone.	Approved
Isoflurane	Isoflurane may increase the QTc-prolonging activities of Ziprasidone.	Approved, Vet Approved
Isosorbide Dinitrate	The metabolism of Isosorbide Dinitrate can be decreased when combined with Ziprasidone.	Approved
Isosorbide Mononitrate	The metabolism of Isosorbide Mononitrate can be decreased when combined with Ziprasidone.	Approved
Isradipine	Isradipine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Itraconazole	The metabolism of Ziprasidone can be decreased when combined with Itraconazole.	Approved, Investigational
Ivabradine	The serum concentration of Ivabradine can be increased when it is combined with Ziprasidone.	Approved
Ivacaftor	The serum concentration of Ivacaftor can be increased when it is combined with Ziprasidone.	Approved
Ivermectin	The metabolism of Ivermectin can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Ixabepilone	The metabolism of Ixabepilone can be decreased when combined with Ziprasidone.	Approved, Investigational
Ixazomib	The metabolism of Ixazomib can be decreased when combined with Ziprasidone.	Approved
Ketamine	The metabolism of Ketamine can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Ketazolam	The metabolism of Ketazolam can be decreased when combined with Ziprasidone.	Approved
Ketobemidone	The metabolism of Ketobemidone can be decreased when combined with Ziprasidone.	Approved
Ketoconazole	The metabolism of Ziprasidone can be decreased when combined with Ketoconazole.	Approved, Investigational
Labetalol	The metabolism of Labetalol can be decreased when combined with Ziprasidone.	Approved
Lamotrigine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Lamotrigine.	Approved, Investigational
Lansoprazole	The metabolism of Lansoprazole can be decreased when combined with Ziprasidone.	Approved, Investigational
Lapatinib	Lapatinib may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Laquinimod	The metabolism of Laquinimod can be decreased when combined with Ziprasidone.	Investigational
Lenvatinib	Lenvatinib may increase the QTc-prolonging activities of Ziprasidone.	Approved
Lercanidipine	The metabolism of Lercanidipine can be decreased when combined with Ziprasidone.	Approved, Investigational
Letrozole	The metabolism of Letrozole can be decreased when combined with Ziprasidone.	Approved, Investigational
Leuprolide	Leuprolide may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Levetiracetam	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Levetiracetam.	Approved, Investigational
Levobupivacaine	The metabolism of Levobupivacaine can be decreased when combined with Ziprasidone.	Approved
Levocabastine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Levocabastine.	Approved
Levocetirizine	The metabolism of Levocetirizine can be decreased when combined with Ziprasidone.	Approved
Levodopa	The therapeutic efficacy of Levodopa can be decreased when used in combination with Ziprasidone.	Approved
Levofloxacin	Levofloxacin may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Levomethadyl Acetate	The metabolism of Levomethadyl Acetate can be decreased when combined with Ziprasidone.	Approved
Levomilnacipran	The metabolism of Levomilnacipran can be decreased when combined with Ziprasidone.	Approved
Levonorgestrel	The metabolism of Levonorgestrel can be decreased when combined with Ziprasidone.	Approved, Investigational
Levorphanol	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Levorphanol.	Approved
Levothyroxine	The metabolism of Levothyroxine can be decreased when combined with Ziprasidone.	Approved
Lidocaine	The metabolism of Lidocaine can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Linagliptin	The therapeutic efficacy of Linagliptin can be decreased when used in combination with Ziprasidone.	Approved
Linezolid	The risk or severity of adverse effects can be increased when Linezolid is combined with Ziprasidone.	Approved, Investigational
Liraglutide	The therapeutic efficacy of Liraglutide can be decreased when used in combination with Ziprasidone.	Approved
Lisdexamfetamine	Ziprasidone may decrease the stimulatory activities of Lisdexamfetamine.	Approved, Investigational
Lisuride	The metabolism of Lisuride can be decreased when combined with Ziprasidone.	Approved
Lithium	Lithium may increase the neurotoxic activities of Ziprasidone.	Approved
Lofentanil	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Lofentanil.	Illicit
Lomitapide	The serum concentration of Lomitapide can be increased when it is combined with Ziprasidone.	Approved
Lomustine	The metabolism of Lomustine can be decreased when combined with Ziprasidone.	Approved
Loperamide	The metabolism of Loperamide can be decreased when combined with Ziprasidone.	Approved
Lopinavir	Ziprasidone may increase the QTc-prolonging activities of Lopinavir.	Approved
Loratadine	The metabolism of Loratadine can be decreased when combined with Ziprasidone.	Approved
Lorazepam	The risk or severity of adverse effects can be increased when Lorazepam is combined with Ziprasidone.	Approved
Lorcaserin	The metabolism of Lorcaserin can be decreased when combined with Ziprasidone.	Approved
Losartan	The metabolism of Losartan can be decreased when combined with Ziprasidone.	Approved
Lovastatin	The metabolism of Ziprasidone can be decreased when combined with Lovastatin.	Approved, Investigational
Loxapine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Loxapine.	Approved
Luliconazole	The serum concentration of Ziprasidone can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The metabolism of Ziprasidone can be increased when combined with Lumacaftor.	Approved
Lumefantrine	Ziprasidone may increase the QTc-prolonging activities of Lumefantrine.	Approved
Lurasidone	The serum concentration of Lurasidone can be increased when it is combined with Ziprasidone.	Approved
Macitentan	The metabolism of Macitentan can be decreased when combined with Ziprasidone.	Approved
Magnesium Sulfate	Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.	Approved, Vet Approved
Maprotiline	Maprotiline may increase the QTc-prolonging activities of Ziprasidone.	Approved
Maraviroc	The metabolism of Maraviroc can be decreased when combined with Ziprasidone.	Approved, Investigational
Mebendazole	The metabolism of Mebendazole can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Meclizine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Meclizine.	Approved
Medetomidine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Medetomidine.	Vet Approved
Medroxyprogesterone acetate	The metabolism of Medroxyprogesterone acetate can be decreased when combined with Ziprasidone.	Approved, Investigational
Mefloquine	Mefloquine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Melatonin	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Melatonin.	Approved, Nutraceutical, Vet Approved
Meloxicam	The metabolism of Meloxicam can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Melperone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Melperone.	Approved
Mephedrone	Ziprasidone may decrease the stimulatory activities of Mephedrone.	Investigational
Mephentermine	Ziprasidone may decrease the stimulatory activities of Mephentermine.	Approved
Mephenytoin	The metabolism of Mephenytoin can be decreased when combined with Ziprasidone.	Investigational, Withdrawn
Mepivacaine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Mepivacaine.	Approved, Vet Approved
Meprobamate	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Meprobamate.	Approved, Illicit
Mequitazine	Ziprasidone may increase the arrhythmogenic activities of Mequitazine.	Approved
Mesoridazine	The metabolism of Mesoridazine can be decreased when combined with Ziprasidone.	Approved
Metaxalone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Metaxalone.	Approved
Metformin	The therapeutic efficacy of Metformin can be decreased when used in combination with Ziprasidone.	Approved
Methadone	Methadone may increase the QTc-prolonging activities of Ziprasidone.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methadyl Acetate.	Approved, Illicit
Methamphetamine	The metabolism of Methamphetamine can be decreased when combined with Ziprasidone.	Approved, Illicit
Methapyrilene	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methapyrilene.	Withdrawn
Methaqualone	The metabolism of Methaqualone can be decreased when combined with Ziprasidone.	Illicit, Withdrawn
Methocarbamol	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methocarbamol.	Approved, Vet Approved
Methohexital	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methohexital.	Approved
Methotrimeprazine	Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.	Approved
Methoxsalen	The metabolism of Methoxsalen can be decreased when combined with Ziprasidone.	Approved
Methoxyflurane	The metabolism of Methoxyflurane can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Methsuximide	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methsuximide.	Approved
Methylecgonine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with ECGONINE METHYL ESTER.	Experimental
Methylphenidate	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylphenidate.	Approved, Investigational
Methylphenobarbital	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylphenobarbital.	Approved
Methylprednisolone	The metabolism of Methylprednisolone can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Methyltestosterone	The metabolism of Methyltestosterone can be decreased when combined with Ziprasidone.	Approved
Methyprylon	The metabolism of Methyprylon can be decreased when combined with Ziprasidone.	Approved, Illicit, Withdrawn
Metoclopramide	The risk or severity of adverse effects can be increased when Metoclopramide is combined with Ziprasidone.	Approved, Investigational
Metoprolol	The serum concentration of Metoprolol can be increased when it is combined with Ziprasidone.	Approved, Investigational
Metronidazole	Metronidazole may increase the QTc-prolonging activities of Ziprasidone.	Approved
Metyrosine	Ziprasidone may increase the sedative activities of Metyrosine.	Approved
Mexiletine	The metabolism of Ziprasidone can be decreased when combined with Mexiletine.	Approved
Mianserin	The metabolism of Mianserin can be decreased when combined with Ziprasidone.	Approved
Mibefradil	The metabolism of Mibefradil can be decreased when combined with Ziprasidone.	Withdrawn
Miconazole	The metabolism of Miconazole can be decreased when combined with Ziprasidone.	Approved, Investigational, Vet Approved
Midazolam	The metabolism of Midazolam can be decreased when combined with Ziprasidone.	Approved, Illicit
Mifepristone	Mifepristone may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Miglitol	The therapeutic efficacy of Miglitol can be decreased when used in combination with Ziprasidone.	Approved
Miglustat	The therapeutic efficacy of Miglustat can be decreased when used in combination with Ziprasidone.	Approved
Milnacipran	The risk or severity of adverse effects can be increased when Milnacipran is combined with Ziprasidone.	Approved
Minaprine	The metabolism of Minaprine can be decreased when combined with Ziprasidone.	Approved
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.	Approved, Investigational
Mirabegron	Mirabegron may increase the QTc-prolonging activities of Ziprasidone.	Approved
Mirtazapine	Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.	Approved
Mitiglinide	The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Ziprasidone.	Approved, Investigational
Mitotane	The serum concentration of Ziprasidone can be decreased when it is combined with Mitotane.	Approved
MMDA	Ziprasidone may decrease the stimulatory activities of MMDA.	Experimental, Illicit
Moclobemide	The metabolism of Moclobemide can be decreased when combined with Ziprasidone.	Approved
Modafinil	The serum concentration of Ziprasidone can be decreased when it is combined with Modafinil.	Approved, Investigational
Moexipril	Moexipril may increase the QTc-prolonging activities of Ziprasidone.	Approved
Molindone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Molindone.	Approved
Montelukast	The metabolism of Montelukast can be decreased when combined with Ziprasidone.	Approved
Morphine	The metabolism of Morphine can be decreased when combined with Ziprasidone.	Approved, Investigational
Moxifloxacin	Moxifloxacin may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Mycophenolate mofetil	The metabolism of Mycophenolate mofetil can be decreased when combined with Ziprasidone.	Approved, Investigational
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.	Approved, Investigational
Nafcillin	The serum concentration of Ziprasidone can be decreased when it is combined with Nafcillin.	Approved
Nalbuphine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Nalbuphine.	Approved
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Ziprasidone.	Approved
Naloxone	The metabolism of Naloxone can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Naratriptan	The risk or severity of adverse effects can be increased when Naratriptan is combined with Ziprasidone.	Approved, Investigational
Nateglinide	The metabolism of Nateglinide can be decreased when combined with Ziprasidone.	Approved, Investigational
Nebivolol	The serum concentration of Nebivolol can be increased when it is combined with Ziprasidone.	Approved, Investigational
Nefazodone	The metabolism of Ziprasidone can be decreased when combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The metabolism of Ziprasidone can be decreased when combined with Nelfinavir.	Approved
Netupitant	The serum concentration of Ziprasidone can be increased when it is combined with Netupitant.	Approved
Nevirapine	The metabolism of Ziprasidone can be increased when combined with Nevirapine.	Approved
Nicardipine	Nicardipine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Nicergoline	The metabolism of Nicergoline can be decreased when combined with Ziprasidone.	Approved
Nicotine	The metabolism of Nicotine can be decreased when combined with Ziprasidone.	Approved
Nifedipine	The metabolism of Nifedipine can be decreased when combined with Ziprasidone.	Approved
Nilotinib	Ziprasidone may increase the QTc-prolonging activities of Nilotinib.	Approved, Investigational
Nilvadipine	The metabolism of Nilvadipine can be decreased when combined with Ziprasidone.	Approved
Nimodipine	The serum concentration of Nimodipine can be increased when it is combined with Ziprasidone.	Approved
Nisoldipine	The metabolism of Nisoldipine can be decreased when combined with Ziprasidone.	Approved
Nitrazepam	The metabolism of Nitrazepam can be decreased when combined with Ziprasidone.	Approved
Nitrendipine	The metabolism of Nitrendipine can be decreased when combined with Ziprasidone.	Approved
Nitrofural	The metabolism of Nitrofural can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Nitrous oxide	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Nitrous oxide.	Approved, Vet Approved
Norethisterone	The metabolism of Norethisterone can be decreased when combined with Ziprasidone.	Approved
Norfloxacin	Norfloxacin may increase the QTc-prolonging activities of Ziprasidone.	Approved
Norflurane	The risk or severity of adverse effects can be increased when Ziprasidone is combined with 1,1,1,2 Tetrafluoroethane.	Investigational
Norgestrel	The metabolism of Norgestrel can be decreased when combined with Ziprasidone.	Approved
Normethadone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Normethadone.	Approved, Illicit
Nortriptyline	Nortriptyline may increase the QTc-prolonging activities of Ziprasidone.	Approved
Octreotide	Octreotide may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Ofloxacin	Ofloxacin may increase the QTc-prolonging activities of Ziprasidone.	Approved
Olanzapine	Olanzapine may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Olaparib	The serum concentration of Olaparib can be increased when it is combined with Ziprasidone.	Approved
Olodaterol	Olodaterol may increase the QTc-prolonging activities of Ziprasidone.	Approved
Olopatadine	The metabolism of Olopatadine can be decreased when combined with Ziprasidone.	Approved
Omeprazole	The metabolism of Omeprazole can be decreased when combined with Ziprasidone.	Approved, Investigational, Vet Approved
Ondansetron	Ondansetron may increase the QTc-prolonging activities of Ziprasidone.	Approved
Opium	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Opium.	Approved, Illicit
Orphenadrine	Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.	Approved
Osanetant	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Osanetant.	Investigational
Osimertinib	The serum concentration of Ziprasidone can be increased when it is combined with Osimertinib.	Approved
Ospemifene	The metabolism of Ospemifene can be decreased when combined with Ziprasidone.	Approved
Oxazepam	The metabolism of Oxazepam can be decreased when combined with Ziprasidone.	Approved
Oxethazaine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Oxetacaine.	Investigational
Oxprenolol	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Oxprenolol.	Approved
Oxybuprocaine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Oxybuprocaine.	Approved
Oxybutynin	The metabolism of Oxybutynin can be decreased when combined with Ziprasidone.	Approved, Investigational
Oxycodone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Oxycodone.	Approved, Illicit, Investigational
Oxymorphone	The metabolism of Oxymorphone can be decreased when combined with Ziprasidone.	Approved, Investigational, Vet Approved
Oxytocin	Oxytocin may increase the QTc-prolonging activities of Ziprasidone.	Approved, Vet Approved
Paclitaxel	The metabolism of Paclitaxel can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Palbociclib	The serum concentration of Ziprasidone can be increased when it is combined with Palbociclib.	Approved
Paliperidone	Ziprasidone may increase the QTc-prolonging activities of Paliperidone.	Approved
Palonosetron	The metabolism of Palonosetron can be decreased when combined with Ziprasidone.	Approved, Investigational
Panobinostat	Panobinostat may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Pantoprazole	The metabolism of Pantoprazole can be decreased when combined with Ziprasidone.	Approved
Paraldehyde	Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.	Approved
Paramethadione	The metabolism of Paramethadione can be decreased when combined with Ziprasidone.	Approved
Paramethasone	The metabolism of Paramethasone can be decreased when combined with Ziprasidone.	Approved
Parecoxib	The metabolism of Parecoxib can be decreased when combined with Ziprasidone.	Approved
Paricalcitol	The metabolism of Paricalcitol can be decreased when combined with Ziprasidone.	Approved, Investigational
Paritaprevir	The metabolism of Paritaprevir can be decreased when combined with Ziprasidone.	Approved
Paroxetine	Paroxetine may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Pasireotide	Pasireotide may increase the QTc-prolonging activities of Ziprasidone.	Approved
Pazopanib	Pazopanib may increase the QTc-prolonging activities of Ziprasidone.	Approved
Peginterferon alfa-2b	The serum concentration of Ziprasidone can be increased when it is combined with Peginterferon alfa-2b.	Approved
Pentamidine	Pentamidine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Pentazocine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Pentazocine.	Approved, Vet Approved
Pentobarbital	The metabolism of Ziprasidone can be increased when combined with Pentobarbital.	Approved, Vet Approved
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.	Approved
Perazine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Perazine.	Investigational
Perflutren	Perflutren may increase the QTc-prolonging activities of Ziprasidone.	Approved
Pergolide	The metabolism of Pergolide can be decreased when combined with Ziprasidone.	Approved, Vet Approved, Withdrawn
Perhexiline	The metabolism of Perhexiline can be decreased when combined with Ziprasidone.	Approved
Permethrin	The metabolism of Permethrin can be decreased when combined with Ziprasidone.	Approved, Investigational
Perospirone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Perospirone.	Approved
Perphenazine	The metabolism of Perphenazine can be decreased when combined with Ziprasidone.	Approved
Pethidine	The metabolism of Pethidine can be decreased when combined with Ziprasidone.	Approved
Phenacetin	The metabolism of Phenacetin can be decreased when combined with Ziprasidone.	Withdrawn
Phenelzine	The risk or severity of adverse effects can be increased when Phenelzine is combined with Ziprasidone.	Approved
Phenformin	The metabolism of Phenformin can be decreased when combined with Ziprasidone.	Approved, Withdrawn
Phenobarbital	The metabolism of Ziprasidone can be increased when combined with Phenobarbital.	Approved
Phenoxybenzamine	The metabolism of Phenoxybenzamine can be decreased when combined with Ziprasidone.	Approved
Phenoxyethanol	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Phenoxyethanol.	Approved
Phenprocoumon	The metabolism of Phenprocoumon can be decreased when combined with Ziprasidone.	Approved
Phentermine	Ziprasidone may decrease the stimulatory activities of Phentermine.	Approved, Illicit
Phenytoin	The metabolism of Ziprasidone can be increased when combined with Phenytoin.	Approved, Vet Approved
Pilocarpine	The metabolism of Pilocarpine can be decreased when combined with Ziprasidone.	Approved
Pimecrolimus	The metabolism of Pimecrolimus can be decreased when combined with Ziprasidone.	Approved, Investigational
Pimozide	The serum concentration of Pimozide can be increased when it is combined with Ziprasidone.	Approved
Pinacidil	The metabolism of Pinacidil can be decreased when combined with Ziprasidone.	Withdrawn
Pindolol	The metabolism of Pindolol can be decreased when combined with Ziprasidone.	Approved
Pioglitazone	The metabolism of Pioglitazone can be decreased when combined with Ziprasidone.	Approved, Investigational
Pipamperone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Pipamperone.	Approved
Piperazine	The metabolism of Piperazine can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Pipotiazine	The metabolism of Pipotiazine can be decreased when combined with Ziprasidone.	Approved
Piribedil	The therapeutic efficacy of Piribedil can be decreased when used in combination with Ziprasidone.	Investigational
Piritramide	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Piritramide.	Investigational
Pizotifen	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Pizotifen.	Approved
Podofilox	The metabolism of Podofilox can be decreased when combined with Ziprasidone.	Approved
Pomalidomide	The metabolism of Pomalidomide can be decreased when combined with Ziprasidone.	Approved
Ponatinib	The metabolism of Ponatinib can be decreased when combined with Ziprasidone.	Approved
Posaconazole	The metabolism of Ziprasidone can be decreased when combined with Posaconazole.	Approved, Investigational, Vet Approved
Pramipexole	Ziprasidone may increase the sedative activities of Pramipexole.	Approved, Investigational
Pramlintide	The therapeutic efficacy of Pramlintide can be decreased when used in combination with Ziprasidone.	Approved, Investigational
Pramocaine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Pramocaine.	Approved
Prasterone	The metabolism of Prasterone can be decreased when combined with Ziprasidone.	Approved, Nutraceutical
Prasugrel	The metabolism of Prasugrel can be decreased when combined with Ziprasidone.	Approved
Pravastatin	The metabolism of Pravastatin can be decreased when combined with Ziprasidone.	Approved
Prazepam	The metabolism of Prazepam can be decreased when combined with Ziprasidone.	Approved, Illicit
Praziquantel	The metabolism of Praziquantel can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Prednisolone	The metabolism of Prednisolone can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Prednisone	The metabolism of Prednisone can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Pregabalin	The risk or severity of adverse effects can be increased when Pregabalin is combined with Ziprasidone.	Approved, Illicit, Investigational
Prilocaine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Prilocaine.	Approved
Primaquine	Primaquine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Primidone	The metabolism of Ziprasidone can be increased when combined with Primidone.	Approved, Vet Approved
Procainamide	Ziprasidone may increase the QTc-prolonging activities of Procainamide.	Approved
Procaine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Procaine.	Approved, Investigational, Vet Approved
Procarbazine	The risk or severity of adverse effects can be increased when Procarbazine is combined with Ziprasidone.	Approved
Prochlorperazine	The metabolism of Prochlorperazine can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Progesterone	The metabolism of Progesterone can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Proguanil	The metabolism of Proguanil can be decreased when combined with Ziprasidone.	Approved
Promazine	Promazine may increase the QTc-prolonging activities of Ziprasidone.	Approved, Vet Approved
Promethazine	Promethazine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Propafenone	The serum concentration of Ziprasidone can be increased when it is combined with Propafenone.	Approved
Proparacaine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Proparacaine.	Approved, Vet Approved
Propofol	Propofol may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational, Vet Approved
Propoxycaine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Propoxycaine.	Approved
Propranolol	The metabolism of Propranolol can be decreased when combined with Ziprasidone.	Approved, Investigational
Protriptyline	Protriptyline may increase the QTc-prolonging activities of Ziprasidone.	Approved
PSD502	The risk or severity of adverse effects can be increased when Ziprasidone is combined with PSD502.	Investigational
Pseudoephedrine	The metabolism of Pseudoephedrine can be decreased when combined with Ziprasidone.	Approved
Pyrazinamide	The metabolism of Pyrazinamide can be decreased when combined with Ziprasidone.	Approved
Quazepam	The metabolism of Quazepam can be decreased when combined with Ziprasidone.	Approved, Illicit
Quetiapine	Ziprasidone may increase the QTc-prolonging activities of Quetiapine.	Approved
Quinacrine	The metabolism of Quinacrine can be decreased when combined with Ziprasidone.	Approved
Quinagolide	The therapeutic efficacy of Quinagolide can be decreased when used in combination with Ziprasidone.	Approved
Quinidine	Ziprasidone may increase the QTc-prolonging activities of Quinidine.	Approved
Quinine	Ziprasidone may increase the QTc-prolonging activities of Quinine.	Approved
Rabeprazole	The metabolism of Rabeprazole can be decreased when combined with Ziprasidone.	Approved, Investigational
Raclopride	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Raclopride.	Investigational
Raloxifene	The metabolism of Raloxifene can be decreased when combined with Ziprasidone.	Approved, Investigational
Ramelteon	The metabolism of Ramelteon can be decreased when combined with Ziprasidone.	Approved, Investigational
Ranitidine	The metabolism of Ranitidine can be decreased when combined with Ziprasidone.	Approved
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Ziprasidone.	Approved, Investigational
Rasagiline	The risk or severity of adverse effects can be increased when Rasagiline is combined with Ziprasidone.	Approved
Reboxetine	The metabolism of Reboxetine can be decreased when combined with Ziprasidone.	Approved, Investigational
Regorafenib	The metabolism of Regorafenib can be decreased when combined with Ziprasidone.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Remifentanil.	Approved
Remoxipride	The metabolism of Remoxipride can be decreased when combined with Ziprasidone.	Approved, Withdrawn
Repaglinide	The metabolism of Repaglinide can be decreased when combined with Ziprasidone.	Approved, Investigational
repinotan	The metabolism of repinotan can be decreased when combined with Ziprasidone.	Investigational
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Ziprasidone.	Approved
Retapamulin	The metabolism of Retapamulin can be decreased when combined with Ziprasidone.	Approved
Rifabutin	The metabolism of Ziprasidone can be increased when combined with Rifabutin.	Approved
Rifampicin	The metabolism of Ziprasidone can be increased when combined with Rifampicin.	Approved
Rifapentine	The metabolism of Ziprasidone can be increased when combined with Rifapentine.	Approved
Rilpivirine	Rilpivirine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Rimonabant	The metabolism of Rimonabant can be decreased when combined with Ziprasidone.	Approved, Investigational
Riociguat	The metabolism of Riociguat can be decreased when combined with Ziprasidone.	Approved
Risperidone	Risperidone may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Ritanserin	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ritanserin.	Investigational
Ritobegron	Ziprasidone may decrease the stimulatory activities of Ritobegron.	Investigational
Ritonavir	The metabolism of Ziprasidone can be decreased when combined with Ritonavir.	Approved, Investigational
Rivaroxaban	The metabolism of Rivaroxaban can be decreased when combined with Ziprasidone.	Approved
Rizatriptan	The risk or severity of adverse effects can be increased when Rizatriptan is combined with Ziprasidone.	Approved
Rofecoxib	The metabolism of Rofecoxib can be decreased when combined with Ziprasidone.	Investigational, Withdrawn
Rolapitant	The metabolism of Rolapitant can be decreased when combined with Ziprasidone.	Approved
Romidepsin	The metabolism of Romidepsin can be decreased when combined with Ziprasidone.	Approved, Investigational
Romifidine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Romifidine.	Vet Approved
Ropinirole	Ziprasidone may increase the sedative activities of Ropinirole.	Approved, Investigational
Ropivacaine	The metabolism of Ropivacaine can be decreased when combined with Ziprasidone.	Approved
Rosiglitazone	The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Ziprasidone.	Approved, Investigational
Rosuvastatin	The metabolism of Rosuvastatin can be decreased when combined with Ziprasidone.	Approved
Rotigotine	Ziprasidone may increase the sedative activities of Rotigotine.	Approved
Roxithromycin	The metabolism of Roxithromycin can be decreased when combined with Ziprasidone.	Approved, Withdrawn
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Ziprasidone.	Approved
Ruxolitinib	The metabolism of Ruxolitinib can be decreased when combined with Ziprasidone.	Approved
Salbutamol	Salbutamol may increase the QTc-prolonging activities of Ziprasidone.	Approved, Vet Approved
Salmeterol	The serum concentration of Salmeterol can be increased when it is combined with Ziprasidone.	Approved
Saquinavir	Saquinavir may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Saxagliptin	The serum concentration of Saxagliptin can be increased when it is combined with Ziprasidone.	Approved
Scopolamine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Scopolamine.	Approved
Secobarbital	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Secobarbital.	Approved, Vet Approved
Selegiline	The metabolism of Selegiline can be decreased when combined with Ziprasidone.	Approved, Investigational, Vet Approved
Selexipag	The metabolism of Selexipag can be decreased when combined with Ziprasidone.	Approved
Sepranolone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Uc1010.	Investigational
Seratrodast	The metabolism of Seratrodast can be decreased when combined with Ziprasidone.	Approved
Sertindole	The metabolism of Sertindole can be decreased when combined with Ziprasidone.	Approved, Withdrawn
Sertraline	Sertraline may increase the QTc-prolonging activities of Ziprasidone.	Approved
Sevoflurane	Sevoflurane may increase the QTc-prolonging activities of Ziprasidone.	Approved, Vet Approved
Sibutramine	The metabolism of Sibutramine can be decreased when combined with Ziprasidone.	Approved, Illicit, Investigational, Withdrawn
Sildenafil	The metabolism of Sildenafil can be decreased when combined with Ziprasidone.	Approved, Investigational
Silodosin	The metabolism of Silodosin can be decreased when combined with Ziprasidone.	Approved
Siltuximab	The serum concentration of Ziprasidone can be decreased when it is combined with Siltuximab.	Approved
Simeprevir	The serum concentration of Simeprevir can be increased when it is combined with Ziprasidone.	Approved
Simvastatin	The metabolism of Simvastatin can be decreased when combined with Ziprasidone.	Approved
Sirolimus	The metabolism of Sirolimus can be decreased when combined with Ziprasidone.	Approved, Investigational
Sitagliptin	The metabolism of Sitagliptin can be decreased when combined with Ziprasidone.	Approved, Investigational
Sodium oxybate	Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.	Approved
Solifenacin	Solifenacin may increase the QTc-prolonging activities of Ziprasidone.	Approved
Sonidegib	The serum concentration of Sonidegib can be increased when it is combined with Ziprasidone.	Approved, Investigational
Sorafenib	Sorafenib may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Sotalol	Ziprasidone may increase the QTc-prolonging activities of Sotalol.	Approved
Sparteine	The metabolism of Sparteine can be decreased when combined with Ziprasidone.	Experimental
Spiramycin	The metabolism of Spiramycin can be decreased when combined with Ziprasidone.	Approved
St. John's Wort	The serum concentration of Ziprasidone can be decreased when it is combined with St. John's Wort.	Nutraceutical
Stiripentol	The serum concentration of Ziprasidone can be increased when it is combined with Stiripentol.	Approved
Sufentanil	The metabolism of Sufentanil can be decreased when combined with Ziprasidone.	Approved, Investigational
Sulfadiazine	The metabolism of Sulfadiazine can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Sulfamethoxazole	Sulfamethoxazole may increase the QTc-prolonging activities of Ziprasidone.	Approved
Sulfinpyrazone	The metabolism of Sulfinpyrazone can be decreased when combined with Ziprasidone.	Approved
Sulfisoxazole	Sulfisoxazole may increase the QTc-prolonging activities of Ziprasidone.	Approved, Vet Approved
Sulodexide	The therapeutic efficacy of Sulodexide can be decreased when used in combination with Ziprasidone.	Approved, Investigational
Sulpiride	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Sulpiride.	Approved
Sumatriptan	The risk or severity of adverse effects can be increased when Sumatriptan is combined with Ziprasidone.	Approved, Investigational
Sunitinib	Sunitinib may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Suvorexant	Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.	Approved
Synthetic Conjugated Estrogens, A	The metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Ziprasidone.	Approved
Synthetic Conjugated Estrogens, B	The metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Ziprasidone.	Approved
Tacrolimus	The metabolism of Tacrolimus can be decreased when combined with Ziprasidone.	Approved, Investigational
Tadalafil	The metabolism of Tadalafil can be decreased when combined with Ziprasidone.	Approved, Investigational
Tamoxifen	The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Ziprasidone resulting in a loss in efficacy.	Approved
Tamsulosin	The metabolism of Tamsulosin can be decreased when combined with Ziprasidone.	Approved, Investigational
Tandospirone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tandospirone.	Investigational
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.	Approved
Tasimelteon	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tasimelteon.	Approved
Tasosartan	The metabolism of Tasosartan can be decreased when combined with Ziprasidone.	Approved
Taurochenodeoxycholic acid	The metabolism of Taurochenodeoxycholic acid can be decreased when combined with Ziprasidone.	Experimental
Tedizolid Phosphate	The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Ziprasidone.	Approved
Tegaserod	The metabolism of Tegaserod can be decreased when combined with Ziprasidone.	Investigational, Withdrawn
Telaprevir	The metabolism of Ziprasidone can be decreased when combined with Telaprevir.	Withdrawn
Telavancin	Telavancin may increase the QTc-prolonging activities of Ziprasidone.	Approved
Telithromycin	Telithromycin may increase the QTc-prolonging activities of Ziprasidone.	Approved
Temazepam	The metabolism of Temazepam can be decreased when combined with Ziprasidone.	Approved
Temsirolimus	The metabolism of Temsirolimus can be decreased when combined with Ziprasidone.	Approved
Teniposide	The metabolism of Teniposide can be decreased when combined with Ziprasidone.	Approved
Tenofovir disoproxil	The metabolism of Ziprasidone can be decreased when combined with Tenofovir.	Approved, Investigational
Terbinafine	The metabolism of Terbinafine can be decreased when combined with Ziprasidone.	Approved, Investigational, Vet Approved
Terbutaline	Terbutaline may increase the QTc-prolonging activities of Ziprasidone.	Approved
Terfenadine	The metabolism of Terfenadine can be decreased when combined with Ziprasidone.	Withdrawn
Teriflunomide	The serum concentration of Ziprasidone can be decreased when it is combined with Teriflunomide.	Approved
Tesmilifene	The metabolism of Tesmilifene can be decreased when combined with Ziprasidone.	Investigational
Testosterone	The metabolism of Testosterone can be decreased when combined with Ziprasidone.	Approved, Investigational
Tetrabenazine	The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Ziprasidone.	Approved
Tetracaine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tetracaine.	Approved, Vet Approved
Tetracycline	The metabolism of Tetracycline can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Tetrodotoxin	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tetrodotoxin.	Investigational
Thalidomide	Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.	Approved, Investigational, Withdrawn
Theophylline	The metabolism of Theophylline can be decreased when combined with Ziprasidone.	Approved
Thiamylal	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Thiamylal.	Approved, Vet Approved
Thiopental	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Thiopental.	Approved, Vet Approved
Thioridazine	The serum concentration of Thioridazine can be increased when it is combined with Ziprasidone.	Withdrawn
Thiotepa	The metabolism of Thiotepa can be decreased when combined with Ziprasidone.	Approved
Thiothixene	Thiothixene may increase the QTc-prolonging activities of Ziprasidone.	Approved
Tiagabine	The metabolism of Tiagabine can be decreased when combined with Ziprasidone.	Approved
Tiapride	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tiapride.	Approved, Investigational
Ticagrelor	The metabolism of Ticagrelor can be decreased when combined with Ziprasidone.	Approved
Ticlopidine	The metabolism of Ziprasidone can be decreased when combined with Ticlopidine.	Approved
Tiletamine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tiletamine.	Vet Approved
Timolol	The metabolism of Timolol can be decreased when combined with Ziprasidone.	Approved
Tinidazole	The metabolism of Tinidazole can be decreased when combined with Ziprasidone.	Approved, Investigational
Tiotropium	The metabolism of Tiotropium can be decreased when combined with Ziprasidone.	Approved
Tipranavir	The metabolism of Tipranavir can be decreased when combined with Ziprasidone.	Approved, Investigational
Tizanidine	Tizanidine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Tocilizumab	The serum concentration of Ziprasidone can be decreased when it is combined with Tocilizumab.	Approved
Tofacitinib	The metabolism of Tofacitinib can be decreased when combined with Ziprasidone.	Approved, Investigational
Tolazamide	The therapeutic efficacy of Tolazamide can be decreased when used in combination with Ziprasidone.	Approved
Tolbutamide	The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ziprasidone.	Approved
Tolcapone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tolcapone.	Approved, Withdrawn
Tolterodine	Tolterodine may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Ziprasidone.	Approved
Topiramate	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Topiramate.	Approved
Toremifene	Ziprasidone may increase the QTc-prolonging activities of Toremifene.	Approved, Investigational
Trabectedin	The serum concentration of Trabectedin can be increased when it is combined with Ziprasidone.	Approved, Investigational
Tramadol	The therapeutic efficacy of Tramadol can be decreased when used in combination with Ziprasidone.	Approved, Investigational
Trans-2-Phenylcyclopropylamine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Trans-2-Phenylcyclopropylamine.	Experimental
Tranylcypromine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Tranylcypromine.	Approved
Trastuzumab emtansine	The metabolism of Trastuzumab emtansine can be decreased when combined with Ziprasidone.	Approved
Trazodone	Trazodone may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Treprostinil	Treprostinil may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Tretinoin	The metabolism of Tretinoin can be decreased when combined with Ziprasidone.	Approved, Investigational, Nutraceutical
Triamcinolone	The metabolism of Triamcinolone can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Triazolam	The metabolism of Triazolam can be decreased when combined with Ziprasidone.	Approved
Trifluoperazine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Trifluoperazine.	Approved
Triflupromazine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Triflupromazine.	Approved, Vet Approved
Trimethadione	The metabolism of Trimethadione can be decreased when combined with Ziprasidone.	Approved
Trimethoprim	Trimethoprim may increase the QTc-prolonging activities of Ziprasidone.	Approved, Vet Approved
Trimipramine	Trimipramine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Triprolidine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Triprolidine.	Approved
Triptorelin	Triptorelin may increase the QTc-prolonging activities of Ziprasidone.	Approved, Vet Approved
Troglitazone	The metabolism of Troglitazone can be decreased when combined with Ziprasidone.	Withdrawn
Udenafil	The metabolism of Udenafil can be decreased when combined with Ziprasidone.	Approved, Investigational
Ulipristal	The serum concentration of Ulipristal can be increased when it is combined with Ziprasidone.	Approved
Umeclidinium	The metabolism of Umeclidinium can be decreased when combined with Ziprasidone.	Approved
Valdecoxib	The metabolism of Valdecoxib can be decreased when combined with Ziprasidone.	Investigational, Withdrawn
Valproic Acid	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Valproic Acid.	Approved, Investigational
Vandetanib	Ziprasidone may increase the QTc-prolonging activities of Vandetanib.	Approved
Vanoxerine	The metabolism of Vanoxerine can be decreased when combined with Ziprasidone.	Investigational
Vardenafil	Vardenafil may increase the QTc-prolonging activities of Ziprasidone.	Approved
Vemurafenib	The serum concentration of Ziprasidone can be increased when it is combined with Vemurafenib.	Approved
Venetoclax	The metabolism of Venetoclax can be decreased when combined with Ziprasidone.	Approved
Venlafaxine	Venlafaxine may increase the QTc-prolonging activities of Ziprasidone.	Approved
Verapamil	The metabolism of Verapamil can be decreased when combined with Ziprasidone.	Approved
Vicriviroc	The metabolism of Vicriviroc can be decreased when combined with Ziprasidone.	Investigational
Vigabatrin	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Vigabatrin.	Approved
Vilanterol	Vilanterol may increase the QTc-prolonging activities of Ziprasidone.	Approved
Vilazodone	The serum concentration of Vilazodone can be increased when it is combined with Ziprasidone.	Approved
Vildagliptin	The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ziprasidone.	Approved, Investigational
Vinblastine	The metabolism of Vinblastine can be decreased when combined with Ziprasidone.	Approved
Vincristine	The metabolism of Vincristine can be decreased when combined with Ziprasidone.	Approved, Investigational
Vindesine	The serum concentration of Vindesine can be increased when it is combined with Ziprasidone.	Approved
Vinorelbine	The metabolism of Vinorelbine can be decreased when combined with Ziprasidone.	Approved, Investigational
Vismodegib	The metabolism of Vismodegib can be decreased when combined with Ziprasidone.	Approved
Voglibose	The therapeutic efficacy of Voglibose can be decreased when used in combination with Ziprasidone.	Approved, Investigational
Voriconazole	The metabolism of Ziprasidone can be decreased when combined with Voriconazole.	Approved, Investigational
Vorinostat	Vorinostat may increase the QTc-prolonging activities of Ziprasidone.	Approved, Investigational
Vortioxetine	The metabolism of Vortioxetine can be decreased when combined with Ziprasidone.	Approved
Warfarin	The metabolism of Warfarin can be decreased when combined with Ziprasidone.	Approved
Xylazine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Xylazine.	Vet Approved
Yohimbine	The metabolism of Yohimbine can be decreased when combined with Ziprasidone.	Approved, Vet Approved
Zafirlukast	The metabolism of Zafirlukast can be decreased when combined with Ziprasidone.	Approved, Investigational
Zalcitabine	The metabolism of Zalcitabine can be decreased when combined with Ziprasidone.	Approved
Zaleplon	The metabolism of Zaleplon can be decreased when combined with Ziprasidone.	Approved, Illicit, Investigational
Ziconotide	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Ziconotide.	Approved
Zidovudine	The metabolism of Zidovudine can be decreased when combined with Ziprasidone.	Approved
Zileuton	The metabolism of Zileuton can be decreased when combined with Ziprasidone.	Approved, Investigational, Withdrawn
Zimelidine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Zimelidine.	Withdrawn
Zolazepam	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Zolazepam.	Vet Approved
Zolmitriptan	The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Ziprasidone.	Approved, Investigational
Zolpidem	Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.	Approved
Zomepirac	The metabolism of Zomepirac can be decreased when combined with Ziprasidone.	Withdrawn
Zonisamide	The metabolism of Zonisamide can be decreased when combined with Ziprasidone.	Approved, Investigational
Zopiclone	The serum concentration of Zopiclone can be increased when it is combined with Ziprasidone.	Approved
Zotepine	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Zotepine.	Approved
Zuclopenthixol	The serum concentration of Zuclopenthixol can be increased when it is combined with Ziprasidone.	Approved, Investigational

Food Interactions

Avoid alcohol.

References

Synthesis Reference

Frank R. Busch, Carol A. Rose, "Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist." U.S. Patent US6110918, issued January, 1995.

US6110918

General References

Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12. [PubMed:14728084 ]
Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH: Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001 Aug 17;425(3):197-201. [PubMed:11513838 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB14391
KEGG Compound	C07568
ChemSpider	54841
BindingDB	50048803
ChEBI	10119
ChEMBL	CHEMBL708
Therapeutic Targets Database	DAP000079
PharmGKB	PA451974
IUPHAR	59
Guide to Pharmacology	59
Drug Product Database	11753
RxList	http://www.rxlist.com/cgi/generic2/ziprasidone.htm
Drugs.com	http://www.drugs.com/cdi/ziprasidone.html
Wikipedia	Ziprasidone

ATC Codes

N05AE04 — Ziprasidone

AHFS Codes

Not Available

PDB Entries

Not Available

FDA label

Download (75 KB)

MSDS

Download (57.8 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Basic Science	Healthy Volunteers	1
1	Completed	Treatment	Healthy Volunteers	2
1	Not Yet Recruiting	Prevention	Cardiovascular Disease (CVD)	1
1, 2	Recruiting	Basic Science	Schizophrenic Disorders	1
2	Completed	Treatment	Autism, Early Infantile	1
2	Completed	Treatment	Bipolar Disorder (BD) / Depression, Bipolar / Depressive State	1
2	Completed	Treatment	Bipolar Disorder (BD) / Schizoaffective Disorders / Schizophrenic Disorders	1
2	Completed	Treatment	Borderline Personality Disorder (BPD)	1
2	Completed	Treatment	Cognition Disorders / Delirium	1
2	Completed	Treatment	Major Depressive Disorder (MDD)	2
2	Completed	Treatment	Oppositional Defiant Disorder	1
2	Completed	Treatment	Psychosis Prodrome	1
2	Completed	Treatment	Schizophrenic Disorders	1
2	Completed	Treatment	Social Anxiety Disorder (SAD)	1
2	Terminated	Not Available	Post-Traumatic Stress Disorder (PTSD)	1
2	Terminated	Treatment	Schizophrenic Disorders	1
2, 3	Completed	Treatment	Affective Disorders	1
2, 3	Completed	Treatment	Schizoaffective Disorders / Schizophrenic Disorders	1
3	Completed	Treatment	Bipolar Disorder (BD)	5
3	Completed	Treatment	Bipolar affective disorder, manic / Bipolar Disorder (BD)	1
3	Completed	Treatment	Bipolar Disorder (BD) / Depression, Bipolar	1
3	Completed	Treatment	Bipolar Disorder (BD) / Major Depressive Disorder (MDD) / Psychosis / Schizoaffective Disorders / Schizophreniform Disorder	1
3	Completed	Treatment	Depressive State	1
3	Completed	Treatment	Psychotic Disorder NOS / Schizophrenic Disorders	1
3	Completed	Treatment	Schizophrenia and Schizoaffective Disorder	1
3	Completed	Treatment	Schizophrenic Disorders	8
3	Recruiting	Treatment	Anxiety Disorder / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders	1
3	Recruiting	Treatment	Autism Spectrum Disorder (ASD)	1
3	Recruiting	Treatment	Bipolar Disorder (BD)	1
3	Recruiting	Treatment	Delirium / Impaired Cognition / Long Term Psychologic Disorders	1
3	Terminated	Treatment	Bipolar Disorder (BD)	1
3	Terminated	Treatment	Bipolar Disorder (BD) / Schizoaffective Disorders / Schizophrenic Disorders	1
3	Terminated	Treatment	Schizoaffective Disorders / Schizophrenic Disorders	1
3	Terminated	Treatment	Schizophrenic Disorders	3
3	Unknown Status	Treatment	Psychosis Nos/Other	1
3	Withdrawn	Treatment	Bipolar Disorder (BD)	2
4	Active Not Recruiting	Treatment	Schizoaffective Disorders / Schizophrenia and Disorders With Psychotic Features / Schizophrenic Disorders	1
4	Completed	Basic Science	Diabetes / Schizophrenic Disorders	1
4	Completed	Diagnostic	Post-Traumatic Stress Disorder (PTSD) / Posttraumatic Stress Disorders / PTSD	1
4	Completed	Treatment	Acute Exacerbation of Psychosis / Delusional Disorder / Mania / Schizophrenic Disorders	1
4	Completed	Treatment	Affective Disorders / Psychotic Disorder NOS / Psychotic Mood Disorder / Schizophrenic Disorders	1
4	Completed	Treatment	Bipolar Disorder (BD)	3
4	Completed	Treatment	Bipolar Disorder (BD) / Depressive State	1
4	Completed	Treatment	Bipolar Disorder (BD) / Generalized Anxiety Disorder (GAD) / Panic Disorders	1
4	Completed	Treatment	Bipolar Disorder (BD) / Mania	1
4	Completed	Treatment	Bipolar Disorder (BD) / Medication Adherence	1
4	Completed	Treatment	Bipolar II Disorder / Major Depressive Episode	1
4	Completed	Treatment	Depression, Bipolar	1
4	Completed	Treatment	Depressive State / Schizoaffective Disorders / Schizophrenic Disorders	1
4	Completed	Treatment	First Episode Psychosis	1
4	Completed	Treatment	Hyperglycemias / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus	1
4	Completed	Treatment	Insulin Resistance / Metabolic Syndromes / Schizophrenic Disorders	1
4	Completed	Treatment	Psychotic Disorder NOS	2
4	Completed	Treatment	Psychotic Disorder NOS / Schizophrenic Disorders	4
4	Completed	Treatment	Pyschotic Disorders	1
4	Completed	Treatment	Schizoaffective Disorders / Schizophrenic Disorders	6
4	Completed	Treatment	Schizophrenia, Schizoaffective Disorder	1
4	Completed	Treatment	Schizophrenic Disorders	8
4	Completed	Treatment	Schizophrenic Disorders / Type 2 Diabetes Mellitus	1
4	Not Yet Recruiting	Treatment	Schizophrenic Disorders	1
4	Recruiting	Treatment	Bipolar Disorder (BD)	1
4	Recruiting	Treatment	Schizophrenic Disorders	1
4	Terminated	Not Available	High Risk MC4R Genotype / Low Risk MC4R Genotype / One Week or Less Antipsychotic Lifetime Exposure	1
4	Terminated	Treatment	Acute Mania / Bipolar Disorder, Manic	1
4	Terminated	Treatment	Bipolar Disorder (BD) / Generalized Anxiety Disorder (GAD)	1
4	Terminated	Treatment	Schizophrenia and Disorders With Psychotic Features	1
4	Unknown Status	Treatment	Schizophrenia or Schizoaffective Disorder	1
4	Unknown Status	Treatment	Schizophrenic Disorders	1
4	Withdrawn	Treatment	Acute Agitation / Delirium / Psychosis	1
Not Available	Completed	Not Available	Affective Psychosis, Bipolar / Mania / Psychoses, Manic-Depressive	1
Not Available	Completed	Not Available	Bipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus	1
Not Available	Completed	Not Available	Bipolar Disorder (BD) / Schizophrenic Disorders	1
Not Available	Completed	Not Available	Psychomotor Agitation	1
Not Available	Completed	Not Available	Schizophrenic Disorders	1
Not Available	Completed	Diagnostic	Obsessive Compulsive Disorder (OCD) / Schizophrenic Disorders	1
Not Available	Completed	Prevention	Hyperglycemias / Hyperlipidemias	1
Not Available	Completed	Treatment	Bipolar Disorder (BD) / Schizoaffective Disorders / Schizophrenic Disorders	1
Not Available	Completed	Treatment	Psychomotor Agitation	1
Not Available	Completed	Treatment	Schizophrenic Disorders	1
Not Available	Completed	Treatment	Schizophrenic Disorders / Type 2 Diabetes Mellitus	1
Not Available	Not Yet Recruiting	Not Available	Bipolar Disorder (BD)	1
Not Available	Recruiting	Not Available	Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / Hospital-acquired bacterial pneumonia / Hypercholesterolaemia / Hyperlipidemias / Hypertensive / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal	1
Not Available	Recruiting	Not Available	Bipolar Disorder (BD)	1
Not Available	Recruiting	Not Available	Micrognathia / Schizophrenic Disorders	1
Not Available	Recruiting	Not Available	Psychomotor Agitation	1
Not Available	Recruiting	Not Available	Schizophrenic Disorders	1

Pharmacoeconomics

Manufacturers

Pfizer inc

Packagers

Ben Venue Laboratories Inc.
Cardinal Health
Comprehensive Consultant Services Inc.
Kaiser Foundation Hospital
Lake Erie Medical and Surgical Supply
Nucare Pharmaceuticals Inc.
Pfizer Inc.
Pharmacia Inc.
Physicians Total Care Inc.
Prepackage Specialists
Rebel Distributors Corp.
Remedy Repack
Resource Optimization and Innovation LLC
Stat Rx Usa
US Pharmaceutical Group

Dosage forms

Form	Route	Strength
Capsule	Oral	20 mg
Injection, powder, lyophilized, for solution	Intramuscular	20 mg/mL
Capsule	Oral	20.0 mg
Capsule	Oral	40 mg
Capsule	Oral	60 mg
Capsule	Oral	80 mg
Capsule	Oral	20 mg/1
Capsule	Oral	40 mg/1
Capsule	Oral	60 mg/1
Capsule	Oral	80 mg/1

Prices

Unit description	Cost	Unit
Zoladex 10.8 mg Implant Syringe	1407.72USD	syringe
Geodon 20 mg vial	16.22USD	vial
Geodon 60 mg capsule	9.88USD	capsule
Geodon 80 mg capsule	9.88USD	capsule
Geodon 20 mg capsule	8.14USD	capsule
Geodon 40 mg capsule	8.14USD	capsule
Zeldox 40 mg Capsule	2.13USD	capsule
Zeldox 60 mg Capsule	2.13USD	capsule
Zeldox 80 mg Capsule	2.13USD	capsule
Zeldox 20 mg Capsule	1.86USD	capsule

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US5134127	No	1993-01-23	2010-01-23	US
CA2256227	No	2003-07-01	2018-12-16	Canada
CA2105114	No	2000-02-15	2013-08-30	Canada
US6245766	No	1998-12-18	2018-12-18	US
US6150366	No	1999-05-27	2019-05-27	US
US6232304	No	1997-04-01	2017-04-01	US
US6399777	No	1997-04-01	2017-04-01	US
US6110918	No	1997-03-26	2017-03-26	US
US7175855	No	2000-05-18	2020-05-18	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	>300 °C	Not Available
logP	3.8	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.00718 mg/mL	ALOGPS
logP	4.64	ALOGPS
logP	4.3	ChemAxon
logS	-4.8	ALOGPS
pKa (Strongest Acidic)	13.18	ChemAxon
pKa (Strongest Basic)	7.09	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	4	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	48.47 Å²	ChemAxon
Rotatable Bond Count	4	ChemAxon
Refractivity	116.72 m³·mol^-1	ChemAxon
Polarizability	44.96 Å³	ChemAxon
Number of Rings	5	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	1.0
Blood Brain Barrier	+	0.9759
Caco-2 permeable	+	0.8867
P-glycoprotein substrate	Substrate	0.7167
P-glycoprotein inhibitor I	Inhibitor	0.8052
P-glycoprotein inhibitor II	Inhibitor	0.6419
Renal organic cation transporter	Inhibitor	0.5325
CYP450 2C9 substrate	Non-substrate	0.7972
CYP450 2D6 substrate	Non-substrate	0.9117
CYP450 3A4 substrate	Substrate	0.7408
CYP450 1A2 substrate	Inhibitor	0.6576
CYP450 2C9 inhibitor	Inhibitor	0.6329
CYP450 2D6 inhibitor	Non-inhibitor	0.7151
CYP450 2C19 inhibitor	Inhibitor	0.8086
CYP450 3A4 inhibitor	Non-inhibitor	0.7723
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.9567
Ames test	Non AMES toxic	0.6273
Carcinogenicity	Non-carcinogens	0.8672
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	2.5877 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.6826
hERG inhibition (predictor II)	Inhibitor	0.7753

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted GC-MS	Predicted GC-MS Spectrum - GC-MS	Not Available
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-01ox-0900400000-0a17dd0e237f50ba91c5	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Organoheterocyclic compounds

Sub Class

Diazinanes

Direct Parent

N-arylpiperazines

Alternative Parents

Benzothiazoles / Phenethylamines / Indoles / Dialkylarylamines / Aralkylamines / N-alkylpiperazines / Aminothiazoles / Aryl chlorides / Imidolactams / Heteroaromatic compounds

Substituents

N-arylpiperazine / 1,2-benzothiazole / Indole / Indole or derivatives / Phenethylamine / Dialkylarylamine / N-alkylpiperazine / Aralkylamine / Imidolactam / Benzenoid

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

organochlorine compound, indolones, piperazines, 1,2-benzisothiazole (CHEBI:10119 )

Structure for DB00246 (Ziprasidone)

Targets

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

References

Enzymes

References

References

References

References

References